[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

US5374772A - Substituted benzoic acids, inhibitors of phospholipases A2 - Google Patents

Substituted benzoic acids, inhibitors of phospholipases A2 Download PDF

Info

Publication number
US5374772A
US5374772A US08/141,309 US14130993A US5374772A US 5374772 A US5374772 A US 5374772A US 14130993 A US14130993 A US 14130993A US 5374772 A US5374772 A US 5374772A
Authority
US
United States
Prior art keywords
benzoic acid
phenoxy
propoxy
octadecyloxy
dihydroxyphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US08/141,309
Inventor
Mathew Carson
Ru-Jen L. Han
Ronald LeMahieu
Vincent S. Madison
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoffmann La Roche Inc
Original Assignee
Hoffmann La Roche Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche Inc filed Critical Hoffmann La Roche Inc
Priority to US08/141,309 priority Critical patent/US5374772A/en
Assigned to HOFFMANN-LA ROCHE INC. reassignment HOFFMANN-LA ROCHE INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CARSON, MATHEW, HAN, RU-JEN LEE, LEMAHIEU, RONALD ANDREW, MADISON, VINCENT STEWART
Application granted granted Critical
Publication of US5374772A publication Critical patent/US5374772A/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/225—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • C07C65/24—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
    • C07C69/92—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with etherified hydroxyl groups

Definitions

  • R is hydrogen, lower alkyl, --(CH 2 ) 2 N(R 3 ) 2 or --CH 2 OOCR 3 wherein R 3 is lower alkyl;
  • R 1 is CH 3 (CH 2 ) n --, wherein n is 0-17, or R 4 (CH 2 ) p --, wherein p is 2-18 and R 4 is 1- or 2-naphthyloxy, 2,3- or 3,4-dihydroxyphenyl, phenyl, phenoxy, or substituted phenyl or phenoxy wherein the substituent is selected from the group consisting of hydroxy, benzyloxy, methylsulfinyl, methylsulfonyl or phenyl;
  • R 2 is R 4 (CH 2 ) p --, 1-adamantyl--CO-- or diphenylmethyl--CO--, and, when R is hydrogen, pharmaceutically acceptable salts with bases.
  • the compounds of formula 1 are potent inhibitors of phospholipases A 2 (PLA 2 's) and are therefore useful in the treatment of diseases, such as psoriasis, inflammatory bowel disease, asthma, allergy, arthritis, dermatitis, gout, pulmonary disease, myocardial ischemia, and trauma induced inflammation, such as spinal cord injury.
  • diseases such as psoriasis, inflammatory bowel disease, asthma, allergy, arthritis, dermatitis, gout, pulmonary disease, myocardial ischemia, and trauma induced inflammation, such as spinal cord injury.
  • the invention relates to compositions and methods of use comprising the compounds of formula 1.
  • Phospholipases A 2 are a class of enzymes which catalyze the hydrolysis of membrane phospholipids at the sn-2 position leading to free fatty acids and lysophospholipid.
  • Arachidonic acid is stored in the cell membrane as an ester almost exclusively at the 2-position of phospholipids.
  • PLA 2 acts to release arachidonic acid from phospholipids in what is believed to be the rate controlling step which ultimately leads to the products of the arachidonic acid cascade.
  • Free arachidonic acid is rapidly metabolized by cyclooxygenase to give prostaglandins and thromboxane or by lipoxygenases to form hydroxy fatty acids and leukotrienes.
  • Prostaglandins and leukotrienes are important mediators of inflammation and hydroxy fatty acids such as leukotriene B 4 act as chemotactic agents for neutrophils and eosinophils and may cause cell migration to sites of inflammation.
  • Lysophospholipids are cytotoxic and have also been implicated in several inflammatory conditions.
  • platelet activating factor (PAF) can be formed by the action of an acetyl transferase on a 1-alkyl-2-lysophospholipid.
  • PAF is a potent platelet aggregating substance and causes various inflammatory conditions such as erythema, vascular permeability and cellular chemotaxis.
  • R is hydrogen, lower alkyl, --(CH 2 ) 2 N(R 3 ) 2 or --CH 2 OOCR 3 wherein R 3 is lower alkyl;
  • R 1 is CH 3 (CH 2 ) n --, wherein n is 0-17, or R 4 (CH 2 ) p --, wherein p is 2-18 and R 4 is 1- or 2-naphthyloxy, 2,3- or 3,4-dihydroxyphenyl, phenyl, phenoxy, or substituted phenyl or phenoxy wherein the substituent is selected from the group consisting of hydroxy, benzyloxy, methylsulfinyl, methylsulfonyl or phenyl;
  • R 2 is R 4 (CH 2 ) p --, 1-adamantyl--CO-- or diphenylmethyl--CO--, and, when R is hydrogen, pharmaceutically acceptable salts with bases.
  • lower alkyl denotes a straight or branched chain saturated hydrocarbon containing 1 to 7 carbon atoms, preferably from 1 to 4 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, butyl, dimethylethyl, neopentyl, pentyl, heptyl, and the like.
  • the preferred compounds of formula 1 can have any of four substitution patterns: ##STR4## wherein R, R 1 and R 2 are as previously described.
  • More preferred compounds of formula 1 are those in which the substitution pattern is 1,3,5 or 1,2,3, preferably 1,3,5;
  • R 1 is CH 3 (CH 2 ) n --, wherein n is 6-17, preferably 9-17;
  • R 2 is 1-adamantyl--CO--, diphenylmethyl--CO--, or R 4 (CH 2 ) p-- , wherein p is 3-10 and R 4 is 2,3- or 3,4-dihydroxyphenyl or substituted phenoxy wherein the substituent is selected from hydroxy, benzyloxy, methylsulfinyl; and R is as previously described.
  • the most preferred compounds of formula 1 are those in which the substitution pattern is 1,3,5;
  • R 1 is CH 3 (CH 2 ) n --, wherein n is 9-17;
  • R 2 is R 4 (CH 2 ) p --, wherein p is 3-8 and R 4 is 2,3-dihydroxyphenyl or substituted phenoxy wherein the substituent is selected from benzyloxy or hydroxy, and R is hydrogen.
  • Preferred compounds of the invention are:
  • R 4 , and p are as defined
  • R 5 is lower alkyl or benzyl
  • a known compound of formula 2 can be converted to the corresponding dialkylated compound of formula 1a by treatment with an excess of the corresponding alkyl halide in the presence of a base, such as an alkali metal carbonate, in a solvent, such as acetone, DMF or mixtures thereof, at a temperature in the range of from 56° to 100°.
  • the resultant ester of formula 1a can be converted to the corresponding acid of formula 1b by base hydrolysis using an alkali metal hydroxide in a solvent, such as methanol with added dioxane, if needed to improve solubility, at temperatures in the range of from 25° to 65°.
  • a known compound of formula 2 can be converted to the corresponding monoalkylated compound of formula 5 by treatment with an equimolar quantity of the corresponding alkyl halide in the presence of a base, such as an alkali metal carbonate, in a solvent, such as acetone, DMF or mixtures thereof, at a temperature in the range of from 56° to 100°.
  • the resultant compound of formula 5 can be converted to the corresponding compound of formula 1c by treatment with a different alkyl halide utilizing the same reaction conditions.
  • Treatment of a compound of formula 5 with 1-adamantanecarboxylic acid chloride or diphenylacetyl chloride provides the corresponding compounds of formula 1c.
  • the R 2 group could be added first followed by the R 1 group.
  • R is --(CH 2 ) 2 N(R 3 ) 2 or --CH 2 OOCR 3 , using known procedures.
  • a dilower alkylaminoethyl chloride such as diethylaminoethyl chloride
  • a chloromethyl lower alkanoate such as chloromethyl acetate
  • a tertiary amine such as triethyl amine or N,N-diisopropylethylamine
  • a solvent such as acetone or DMF
  • esters 1a and 1c where R 5 is lower alkyl by treatment with the corresponding lower alkyl halide, preferably the iodide, in the presence of an alkali metal bicarbonate in a solvent, such as, DMF at temperatures in the range of from 25° to 100°.
  • R 1 and p are as defined and Bn is benzyl
  • R 1 or R 2 in 1d contain a benzyloxy substituent
  • such compounds (1e or 1g) can be converted to the corresponding hydroxy derivatives 1f and 1h, respectively according to Scheme 3. This can be accomplished by catalytic hydrogenolysis under the standard conditions described above.
  • the invention also relates to salts of the compounds of formula 1 when they contain an acidic functionality, such as when R is hydrogen, which lends itself to salt formation with a base.
  • Salts of the compounds of formula 1 which have a carboxy group are prepared by the reaction with a base having a non-toxic, pharmacologically acceptable cation.
  • any base which will form a salt with a carboxylic acid and whose pharmacological properties will not cause an adverse physiological effect is within the scope of this invention.
  • Suitable bases thus include, for example, the alkali metal and alkaline earth metal hydroxides, carbonates or the like, for example, calcium hydroxide, sodium hydroxide, sodium carbonate, potassium carbonate or the like, ammonia, primary, secondary and tertiary amines, such as monoalkylamines, dialkylamines, trialkylamines, for example, methylamine, diethylamine, triethylamine or the like, nitrogen containing heterocyclic amines, for example, piperidine or the like.
  • the alkali metal and alkaline earth metal hydroxides, carbonates or the like for example, calcium hydroxide, sodium hydroxide, sodium carbonate, potassium carbonate or the like, ammonia, primary, secondary and tertiary amines, such as monoalkylamines, dialkylamines, trialkylamines, for example, methylamine, diethylamine, triethylamine or the like, nitrogen containing heterocyclic amines, for example
  • a salt thus produced is the functional equivalent of the corresponding compound of formula 1 wherein R is hydrogen and one skilled in the art will appreciate that the variety of salts embraced by the invention is limited only by the criterion that a base employed in forming the corresponding salts be both non-toxic and physiologically acceptable.
  • the compounds of formula 1 are potent inhibitors of phospholipases A 2 (PLA 2 's) and are therefore useful in the treatment of diseases, such as psoriasis, inflammatory bowel disease, asthma, allergy, arthritis, dermatitis, gout, pulmonary disease, myocardial ischemia, and trauma induced inflammation, such as spinal cord injury.
  • diseases such as psoriasis, inflammatory bowel disease, asthma, allergy, arthritis, dermatitis, gout, pulmonary disease, myocardial ischemia, and trauma induced inflammation, such as spinal cord injury.
  • the PLA 2 used in this test is the extracellular enzyme obtained from human synovial fluid (HSF-PLA 2 ).
  • the assay for HSF-PLA 2 activity was a modification of the described method [Franson R., Dobrow R., Weiss, J., Elsbach P., and Weglick W. B., J. Lipid Res., 19, 18-23 (1978)] which was conducted using [1- 14 C]-oleate-labelled E. coli substrate in excess at a final concentration of 20,000 dpm/ml. This was equivalent to 18.2 mM of cell membrane phospholipid phosphorus and 2 ⁇ 10 9 autoclaved E. coli/ml.
  • the optimal conditions which were developed for the assay of HSF-PLA 2 inhibitors are summarized as follows.
  • a total volume of 0.5 ml of reaction mixture typically had the following final composition: substrate (20,000 dpm/ml); enzyme (0.1% HSF, v/v); 2 mM CaCl 2 ; 150 mM Na + ; 50 mM sodium HEPES buffer, pH 7.3; and 1% dimethyl sulfoxide (DMSO, used to solubilize test inhibitors) in the presence or absence of inhibitor.
  • substrate 20,000 dpm/ml
  • enzyme 0.1% HSF, v/v
  • 2 mM CaCl 2 150 mM Na + ; 50 mM sodium HEPES buffer, pH 7.3; and 1% dimethyl sulfoxide (DMSO, used to solubilize test inhibitors) in the presence or absence of inhibitor.
  • DMSO dimethyl sulfoxide
  • the extraction of lipids from the stopped reaction mixture was conducted by the further additions of 0.5 ml of chloroform and 1 ml of water with mixing. After centrifuging, the lower chloroform phase was transferred to smaller glass tubes and the solvent was evaporated to dryness with a nitrogen stream. The extracted lipid residue was redissolved in 50 ml of a solution containing carrier oleic acid (0.2 mg/ml) of chloroformmethanol [9 to 1, v/v]).
  • the whole lipid extract was applied to a preactivated (30 minutes at 110° C.) silica gel-impregnated glass fiber thin layer chromatography sheet (ITLC type SG sheet from Gelman Sciences Inc., Ann Arbor, Mich.) using hexane-acetic acid (100 to 1, v/v) as the developing solvent.
  • This TLC system rapidly (6 minutes) resolved the enzymatically released product, 14 C-oleic acid, from the unreacted 14 C-phospholipid substrate.
  • the unsaturated lipids were located on the chromatogram by a brief exposure to iodine vapor.
  • the oleic acid zone (R f value 0.95) and phospholipid zone (origin) were cut out, chopped into small pieces, shaken with 2 ml of ethanol-water (80 to 20, v/v) and 15 ml of Aquasol and counted for radioactivity.
  • a control incubation of substrate in the absence of HSF-PLA 2 was performed in each experiment.
  • the PLA 2 activity of the human synovial fluid was corrected for this small control value. In the absence of inhibitors, these optimal conditions resulted in approximately 18% hydrolysis of substrate (corrected for a substrate blank of ⁇ 2%).
  • the specific activity of PLA 2 in the pooled human synovial fluid under the optimal assay conditions was 49.2 nmoles [1- 14 C]-oleic acid released hour -1 mg -1 .
  • the IC 50 ( ⁇ M concentration of test compound that produces 50% inhibition of PLA 2 activity) was determined for each test compound. The results are reported in Tables I and II.
  • the croton oil-induced mouse ear edema test a model of irritant-induced contact dermatitis, has been used for evaluation of the PLA 2 inhibitors by the topical route of administration. This test was carried out as described in the following references:
  • TPA tumor promoter 12-O-tetradecanoylphorbol-13-acetate
  • Indomethacin an inhibitor of prostaglandin synthesis, prevented the TPA-mediated increase in epidermal PGE 2 levels as well as the TPA-mediated induction of epidermal cell ornithine decarboxylase.
  • the application of PGE 2 to mouse skin countered the inhibitory effect of indomethacin upon TPA-stimulated cellular proliferation.
  • TPA-induced mouse ear edema test a model of irritant-induced contact dermatitis is described in the following reference: J. M. Young, B. M. Wagner and D. A. Spires, J. Invest. Dermatology 80, 48-52 (1983).
  • TPA 12-O-tetradecanoylphorbol-13-acetate
  • vehicle of pyridine: water: diethyl ether (20:5:75) was applied to the outside of the right ear of 3-4 week old male CD-1 mice (8 animals per group).
  • the test compounds were dissolved in the same vehicle and 10 ⁇ l was applied to the inside of the same ear 30 minutes prior to the application of TPA.
  • Ear punches (6 mm) were removed at 6 hours after TPA application, weighed and assayed for myeloperoxidase (MPO) activity as described in the following reference: P. P. Bradley, D. A. Priebat, R. D. Christensen and G. Rothstein, J.
  • MPO myeloperoxidase
  • the wet weight of the ear biopsy punches is a measure of the ear edema and the level of MPO activity in the ear punches is an indicator of neutrophil infiltration.
  • the data are expressed as percent inhibition of drug-treated animals relative to the control group.
  • Representative compounds of the invention were tested in rats to determine their ability to inhibit the acute inflammatory response induced by the injection of snake venom phospholipase A 2 .
  • Test compounds were administered intraperitoneally or orally to groups of seven Lewis rats ( ⁇ 200 gm) 1 hr prior to phospholipase A 2 administration.
  • the test compounds were dissolved in dimethyl sulfoxide for intraperitoneal administration and dissolved or suspended in Labrafil M-1944CS for oral administration.
  • 5 ⁇ g (10 units) of purified phospholipase A 2 from Naja naja venom Sigma Chem.
  • the volume (in mL) of the fight hind paw was measured by immersion of the paw to the level of the lateral malleolus in an aqueous plethysmometer immediately prior to the injection of phospholipase A 2 and then at 0.5, 2 and 4 hr after phospholipase A 2 injection.
  • the paw edema was calculated by subtracting the zero time reading from the readings taken after injection. The percent change of the edema volume from the vehicle treated control was calculated to determine the activity of the test compound.
  • Representative compounds of the invention were tested in the rat carrageenan-induced paw edema test to determine their ability to inhibit this acute inflammatory response.
  • Test compounds were administered intraperitoneally or orally to groups of seven Lewis rats ( ⁇ 200 gm) 1 hr prior to carrageenan administration.
  • the test compounds were dissolved in dimethyl sulfoxide for intraperitoneal administration and dissolved or suspended in Labrafil M-19944CS for oral administration.
  • 0.1 mL of 1% carrageenan dissolved in pyrogen free saline was injected subplantarly into the right hind paw to elicit the inflammatory response.
  • the volume (in mL) of the right hind paw was measured by immersion of the paw to the level of the lateral malleolus in an aqueous plethysmometer immediately prior to the injection of carrageenan and then at 1, 2 and 4 hr after carrageenan injection.
  • the paw edema was calculated by subtracting the zero time reading from the readings taken after injection.
  • the percent change of the edema volume from the vehicle treated control was calculated to determine the activity of the test compound.
  • Statistical analysis of the mean paw edema values of the control versus the treated groups was performed using Student's t-test.
  • Acetic acid-induced colitis is characterized by the movement of inflammatory cells into the colon, ,with the number of such cells in the mucosa being measured by the activity of myeloperoxidase, a marker enzyme for these cells. Positive desirable activity is indicated by a reduction in the high levels of myeloperoxidase caused by acetic acid.
  • mice Male rats (Sprague-Dawley), weighing 150 to 300 g, were pretreated twice daily for two days with either the vehicle (water or dimethylsulfoxide) or the test inhibitor compound suspended in water or dissolved in dimethylsulfoxide and orally administered. On the third day, the animals were dosed the same as on the previous two days, anesthetized with metofane, and 2 ml of 2.5% acetic acid was injected by syringe into the colonic lumen, followed immediately by 3 ml of air and a rinse consisting of 3 ml of phosphate-buffered saline (the acetic acid is present in the lumen for a sufficient period to cause inflammation without producing severe necrosis or irreversible damage).
  • vehicle water or dimethylsulfoxide
  • test inhibitor compound suspended in water or dissolved in dimethylsulfoxide and orally administered.
  • the animals were dosed the same as on the previous two days, anesthetized with metofane, and 2 ml
  • the animals were administered a second dose of the test compound in the same amount about 16 hours later. Then 24 hours after the acetic acid treatment, the animals were sacrificed.
  • the colonic mucosa was surgically removed and homogenized in an aqueous buffer at pH 6 with a Tissumizer or similar device and myeloperoxidase was measured in the homogenate using o-phenylenediamine as a chromagen, as described by A. Voller, D. E. Bidwell and A. Bartlett in "The Enzyme Linked Immunosorbent Assay (ELISA)", Zoological Soc., London, 1979, pages 29-30. Control animals were pretreated with the vehicle and saline in place of acetic acid.
  • ELISA Enzyme Linked Immunosorbent Assay
  • the dose of a compound of formula 1 or a salt thereof to be administered and the frequency of administration will be dependent on the potency and duration of activity of the particular compound of formula 1 or salt to be administered and on the route of administration, as well as the severity and nature of the condition and age of the mammal to be treated and the like.
  • Oral doses of a compound of formula 1 or a salt thereof contemplated for use in practicing the invention can be in the range of from 10 mg to about 2.0 g per day, preferably about 50 mg to about 1 g per day, either as a single dose or in divided doses.
  • a compound of formula I or salt thereof contemplated for use in practicing the invention is present in the topical composition in the range of from about 1 to about 10%, preferably from about 2 to about 5%.
  • a compound of formula 1, or a salt or a composition containing a therapeutically effective amount of a compound of formula 1, or a salt thereof can be administered by methods well known in the art.
  • a compound of formula 1, or a salt thereof can be administered either singly or with other pharmaceutical agents, for example, antihistamines, mediator release inhibitors, methyl xanthines, beta agonists or antiasthmatic steroids such as prednisone and prednisolone, orally, parenterally, rectally, or by inhalation, for example in the form of an aerosol, micropulverized powder or nebulized solution.
  • oral administration they can be administered in the form of tablets, capsules, for example, in admixture with talc, starch, milk sugar or other inert ingredients, that is, pharmaceutically acceptable carriers, or in the form of aqueous solutions, suspensions, elixirs or aqueous alcoholic solutions, for example, in admixture with sugar or other sweetening agents, flavoring agents, colorants, thickeners and other conventional pharmaceutical excipients.
  • parenteral administration they can be administered as solutions or suspension, for example, as an aqueous or peanut oil suspension using excipients and carriers conventional for this mode of administration.
  • aerosols For administration as aerosols, they can be dissolved in a suitable pharmaceutically acceptable solvent, for example, ethyl alcohol or combinations of miscible solvents, and mixed with a pharmaceutically acceptable propellant.
  • a suitable pharmaceutically acceptable solvent for example, ethyl alcohol or combinations of miscible solvents
  • Such aerosol compositions are packaged for use in pressurized container fitted with an aerosol valve suitable for release of the pressurized composition.
  • the aerosol valve is a metered valve, that is one which on activation releases a predetermined effective dose of the aerosol composition.
  • they can conveniently be used in the form of salves, tinctures, creams, solutions, lotions, sprays, suspensions and the like. Salves and creams as well as solutions are preferred.
  • These topical preparations can be prepared by mixing a compound of formula I as an active ingredient with one or more non-toxic, inert, solid or liquid carriers which are usual in such preparations and which are suitable for topical treatment.
  • 1-Adamantane carboxylic acid chloride (0.067 g) in 1 ml of methylene chloride was added to a stirred solution of 0.153 g of 3-hydroxy-5-(octadecyloxy)benzoic acid phenylmethyl ester and 0.09 ml of triethylamine in 10 ml of methylene chloride.
  • the reaction mixture was stirred at room temperature for 17 hours and was then washed with 1N HCl and with NaHCO 3 solution.
  • the filtrate was concentrated to a solid which was recrystallized from methylene chloride-methanol to give 1.77 g, mp 134°-136°, of 3,5-bis[3-[4-(phenylmethoxy)phenoxy]propoxy]benzoic acid methyl ester.
  • the filtrate was concentrated to a solid which was purified by chromatography on 20 g of silica gel (230-400 mesh) using 10% ethyl acetate-hexane to give 1.47 g (30% yield, mp 120°-122°) of 3-hydroxy-5-[3-[4-(phenylmethoxy)phenoxy]propoxy]benzoic acid methyl ester.
  • Step 3 Add the oil soluble preservatives to the lipid phase (Step 1). Mix until dissolved.
  • Step 3 Dissolve the drug in the lipid phase from Step 3. Mix vigorously until the drug is dissolved.
  • Step 2 Add Step 2 to Step 4. Homogenize until a uniform emulsion is formed.
  • Step 3 Add the oil soluble preservatives to the lipid phase of Step 1. Mix until dissolved.
  • Step 3 Dissolve the drug in the lipid phase from Step 3. Mix vigorously until the drug is dissolved.
  • Step 2 Add Step 2 to Step 4. Homogenize until a uniform emulsion is formed.
  • Step 3 Add the drug to Step 2. Mix vigorously until drug is dissolved.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to compounds of the formula ##STR1## R is hydrogen, lower alkyl, --(CH2)2 N(R3)2 or --CH2 OOCR3 wherein R3 is lower alkyl;
R1 is CH3 (CH2)n --, wherein n is 0-17, or R4 (CH2)p --, wherein p is 2-18 and R4 is 1- or 2-naphthyloxy, 2,3- or 3,4-dihydroxyphenyl, phenyl, phenoxy, or substituted phenyl or phenoxy wherein the substituent is selected from the group consisting of hydroxy, benzyloxy, methylsulfinyl, methylsulfonyl or phenyl;
R2 is R4 (CH2)p --, 1-adamantyl--CO-- or diphenylmethyl--CO--, and, when R is hydrogen, pharmaceutically acceptable salts with bases.
The compounds of formula I are potent inhibitors of phospholipases A2 (PLA2 's) and are therefore useful in the treatment of diseases, such as psoriasis, inflammatory bowel disease, asthma, allergy, arthritis, dermatitis, gout, pulmonary disease, myocardial ischemia, and trauma induced inflammation, such as spinal cord injury.

Description

This application is a Continuation-in-part of Ser. No. 07/987,227, filed Dec. 8, 1992 now abandoned.
BRIEF SUMMARY OF THE INVENTION
The invention relates to compounds of the formula ##STR2## R is hydrogen, lower alkyl, --(CH2)2 N(R3)2 or --CH2 OOCR3 wherein R3 is lower alkyl;
R1 is CH3 (CH2)n --, wherein n is 0-17, or R4 (CH2)p --, wherein p is 2-18 and R4 is 1- or 2-naphthyloxy, 2,3- or 3,4-dihydroxyphenyl, phenyl, phenoxy, or substituted phenyl or phenoxy wherein the substituent is selected from the group consisting of hydroxy, benzyloxy, methylsulfinyl, methylsulfonyl or phenyl;
R2 is R4 (CH2)p --, 1-adamantyl--CO-- or diphenylmethyl--CO--, and, when R is hydrogen, pharmaceutically acceptable salts with bases.
The compounds of formula 1 are potent inhibitors of phospholipases A2 (PLA2 's) and are therefore useful in the treatment of diseases, such as psoriasis, inflammatory bowel disease, asthma, allergy, arthritis, dermatitis, gout, pulmonary disease, myocardial ischemia, and trauma induced inflammation, such as spinal cord injury.
In another aspect, the invention relates to compositions and methods of use comprising the compounds of formula 1.
BACKGROUND OF THE INVENTION
Phospholipases A2 (PLA2 's) are a class of enzymes which catalyze the hydrolysis of membrane phospholipids at the sn-2 position leading to free fatty acids and lysophospholipid. Arachidonic acid is stored in the cell membrane as an ester almost exclusively at the 2-position of phospholipids. PLA2 acts to release arachidonic acid from phospholipids in what is believed to be the rate controlling step which ultimately leads to the products of the arachidonic acid cascade. Free arachidonic acid is rapidly metabolized by cyclooxygenase to give prostaglandins and thromboxane or by lipoxygenases to form hydroxy fatty acids and leukotrienes. Prostaglandins and leukotrienes are important mediators of inflammation and hydroxy fatty acids such as leukotriene B4 act as chemotactic agents for neutrophils and eosinophils and may cause cell migration to sites of inflammation. Lysophospholipids are cytotoxic and have also been implicated in several inflammatory conditions. In addition, platelet activating factor (PAF) can be formed by the action of an acetyl transferase on a 1-alkyl-2-lysophospholipid. PAF is a potent platelet aggregating substance and causes various inflammatory conditions such as erythema, vascular permeability and cellular chemotaxis. These facts provide support for the utilization of an inhibitor of PLA2 's as therapy for various inflammatory conditions.
DETAILED DESCRIPTION OF THE INVENTION
The invention relates to compounds of the formula ##STR3## R is hydrogen, lower alkyl, --(CH2)2 N(R3)2 or --CH2 OOCR3 wherein R3 is lower alkyl;
R1 is CH3 (CH2)n --, wherein n is 0-17, or R4 (CH2)p --, wherein p is 2-18 and R4 is 1- or 2-naphthyloxy, 2,3- or 3,4-dihydroxyphenyl, phenyl, phenoxy, or substituted phenyl or phenoxy wherein the substituent is selected from the group consisting of hydroxy, benzyloxy, methylsulfinyl, methylsulfonyl or phenyl;
R2 is R4 (CH2)p --, 1-adamantyl--CO-- or diphenylmethyl--CO--, and, when R is hydrogen, pharmaceutically acceptable salts with bases.
As used herein, the term "lower alkyl", alone or in combination, denotes a straight or branched chain saturated hydrocarbon containing 1 to 7 carbon atoms, preferably from 1 to 4 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, butyl, dimethylethyl, neopentyl, pentyl, heptyl, and the like.
The preferred compounds of formula 1 can have any of four substitution patterns: ##STR4## wherein R, R1 and R2 are as previously described.
More preferred compounds of formula 1 are those in which the substitution pattern is 1,3,5 or 1,2,3, preferably 1,3,5;
R1 is CH3 (CH2)n --, wherein n is 6-17, preferably 9-17;
R2 is 1-adamantyl--CO--, diphenylmethyl--CO--, or R4 (CH2)p--, wherein p is 3-10 and R4 is 2,3- or 3,4-dihydroxyphenyl or substituted phenoxy wherein the substituent is selected from hydroxy, benzyloxy, methylsulfinyl; and R is as previously described.
The most preferred compounds of formula 1 are those in which the substitution pattern is 1,3,5;
R1 is CH3 (CH2)n --, wherein n is 9-17;
R2 is R4 (CH2)p --, wherein p is 3-8 and R4 is 2,3-dihydroxyphenyl or substituted phenoxy wherein the substituent is selected from benzyloxy or hydroxy, and R is hydrogen.
Preferred compounds of the invention are:
3-[[6-(2,3-dihydroxyphenyl)hexyl]oxy]-5-(octadecyloxy)benzoic acid;
3-[3-(4-hydroxyphenoxy)propoxy]-5-(octadecyloxy)benzoic acid;
3-[3-(4-hydroxyphenoxy)propoxy]-5-(tetradecyloxy)benzoic acid;
3-(decyloxy)-5-[3-(4-hydroxyphenoxy)propoxy]benzoic acid:
3-[[6-(2,3-dihydroxyphenyl)hexyl]oxy]-5-(tetradecyloxy)benzoic acid;
3-(decyloxy)-5-[[6-(2,3-dihydroxyphenyl)hexyl]oxy]benzoic acid;
3-(octadecyloxy)-5-(2,2-diphenyl-1-oxoethoxy)benzoic acid;
3-(octadecyloxy)-5-[(tricyclo[3.3.1./3,7/]dec-1-ylcarbonyl)oxy]benzoic acid;
3-(octadecyloxy)-5-(3-phenoxypropoxy)benzoic acid;
3-[[3-(4-phenylmethoxy)phenoxy]propoxy]-5-(octadecyloxy)benzoic acid;
3-[[6-(2,3-dihydroxyphenyl)hexyl]oxy]-5-(octadecyloxy)benzoic acid methyl ester;
3-[3-(4-hydroxyphenoxy)propoxy]-5-(octadecyloxy)benzoic acid methyl ester;
3-[[6-(2,3-dihydroxyphenyl)hexyl]oxy]-5-(tetradecyloxy)benzoic acid methyl ester;
3-(decyloxy)-5-[[6-(2,3-dihydroxyphenyl)hexyl]oxy]benzoic acid methyl ester, and
2-[3-(4-hydroxyphenoxy)propoxy]-3-(octadecyloxy)benzoic acid.
Exemplary of other compounds of the invention are:
3-[3-(4-hydroxyphenoxy)propoxy]-5-(octyloxy)benzoic acid;
3-(dodecyloxy)-5-[3-(4-hydroxyphenoxy)propoxy]benzoic acid;
3-(hexyldecyloxy)-5-[3-(4-hydroxyphenoxy)propoxy]benzoic acid;
3-[4-(4-hydroxyphenoxy)butoxy]-5-(octyloxy)benzoic acid;
3-[4-(4-hydroxyphenoxy)butoxy]-5-(octyloxy)benzoic acid;
3-[[8-(4-hydroxyphenoxy)octyl]oxy]-5-(octyloxy)benzoic acid;
3-[3-(3-hydroxyphenoxy)propoxy]-5-(octyloxy)benzoic acid;
3-[3-(4-phenylphenoxy)propoxy]-5-(octyloxy)benzoic acid;
2-[3-(4-hydroxyphenoxy)propoxy]-3-(tetradecyloxy)benzoic acid;
2-[3-(4-hydroxyphenoxy)propoxy]-3-(hexadecyloxy)benzoic acid;
2-[3-(4-hydroxyphenoxy)propoxy]-3-(decyloxy)benzoic acid;
2-[3-(2-hydroxyphenoxy)propoxy]-3-(tetradecyloxy)benzoic acid;
2-[3-(2-hydroxyphenoxy)propoxy]-3-(octadecyloxy)benzoic acid;
2-[[6-(4-hydroxyphenoxy)hexyl]oxy]-3-(tetradecyloxy)benzoic acid;
2-[[8-(4-hydroxyphenoxy)octyl]oxy]-3-(tetradecyloxy)benzoic acid;
2-[[6-(2-hydroxyphenoxy)hexyl]oxy]-3-(tetradecyloxy)benzoic acid;
2-[[6-(2,3-dihydroxyphenyl)hexyl]oxy]-3-(octadecyloxy)benzoic acid;
2-[3-(2,3-dihydroxyphenyl)propoxy]-3-(octadecyloxy)benzoic acid;
2-[[6-(2,3-dihydroxyphenyl)hexyl]oxy]-3-(tetradecyloxy)benzoic acid;
2-[[6-(2,3-dihydroxyphenyl)hexyl]oxy]-3-(decyloxy)benzoic acid;
3-[[6-(2,3-dihydroxyphenyl)hexyl]oxy]-5-(dodecyloxy)benzoic acid;
3-[[6-(2,3-dihydroxyphenyl)hexyl]oxy]-5-(hexadecyloxy)benzoic acid;
3-[3-(2,3-dihydroxyphenyl)propoxy]-5-(octadecyloxy)benzoic acid;
3-[4-(2,3-dihydroxyphenyl)butoxy]-5-(octadecyloxy)benzoic acid;
3-[[5-(2,3-dihydroxyphenyl)pent]oxy]-5-(octadecyloxy)benzoic acid;
3-[[8-(2,3-dihydroxyphenyl)octyl]oxy]-5-(hexadecyloxy)benzoic acid;
3-[[6-(3,4-dihydroxyphenyl)hexyl]oxy]-5-(octadecyloxy)benzoic acid;
3-[[6-(3,4-dihydroxyphenyl)hexyl]oxy]-5-(decyloxy)benzoic acid;
3-[[6-(3,4-dihydroxyphenyl)hexyl]oxy]-5-(tetradecyloxy)benzoic acid;
3-(tetradecyloxy)-5-(2,2-diphenyl-1-oxoethoxy)benzoic acid;
3-(decyloxy)-5-(2,2-diphenyl-1-oxoethoxy)benzoic acid;
3-(tetradecyloxy)-5-[(tricyclo[3.3.1./3,7/]dec-1-ylcarbonyl)oxy]benzoic acid, and
3-(decyloxy)-5-[(tricyclo[3.3.1./3,7/]dec-1-ylcarbonyl)oxy]benzoic acid.
The compounds of formula I can be prepared as set forth in Schemes 1-3. ##STR5## wherein R1 a and R2 a are the same, and are
R4 (CH2)p --
R4, and p are as defined
R5 is lower alkyl or benzyl
In Scheme 1, a known compound of formula 2 can be converted to the corresponding dialkylated compound of formula 1a by treatment with an excess of the corresponding alkyl halide in the presence of a base, such as an alkali metal carbonate, in a solvent, such as acetone, DMF or mixtures thereof, at a temperature in the range of from 56° to 100°. The resultant ester of formula 1a can be converted to the corresponding acid of formula 1b by base hydrolysis using an alkali metal hydroxide in a solvent, such as methanol with added dioxane, if needed to improve solubility, at temperatures in the range of from 25° to 65°. Compounds of formula 1a, wherein R5 is benzyl, can also be converted to compounds of formula 1b by catalytic hydrogenolysis under standard conditions, such as shaking under a hydrogen atmosphere, in a solvent, such as THF or ethyl acetate, in the presence of a catalyst, such as palladium. ##STR6## wherein R1 and R2 are not the same and are as previously described and R5 is also as previously described.
In Scheme 2, a known compound of formula 2 can be converted to the corresponding monoalkylated compound of formula 5 by treatment with an equimolar quantity of the corresponding alkyl halide in the presence of a base, such as an alkali metal carbonate, in a solvent, such as acetone, DMF or mixtures thereof, at a temperature in the range of from 56° to 100°. The resultant compound of formula 5 can be converted to the corresponding compound of formula 1c by treatment with a different alkyl halide utilizing the same reaction conditions. Treatment of a compound of formula 5 with 1-adamantanecarboxylic acid chloride or diphenylacetyl chloride provides the corresponding compounds of formula 1c. wherein R2 is 1-adamantyl--CO-- or diphenylmethyl--CO--. Finally, base hydrolysis of 1c using an alkali metal hydroxide in a solvent, such as methanol with added dioxane, if needed to improve solubility, at temperatures in the range of from 25° to 65°. Compounds of formula 1c, wherein R5 is benzyl, can also be converted to compounds of formula 1d by catalytic hydrogenolysis under standard conditions, such as shaking under a hydrogen atmosphere, in a solvent, such as THF or ethyl acetate, in the presence of a catalyst, such as palladium. When R2 is 1-adamantyl--CO-- or diphenylmethyl--CO-- and R5 is benzyl in 1c, catalytic hydrogenolysis must be used to convert 1c to 1d.
Alternatively, the R2 group could be added first followed by the R1 group.
The acids of formulas 1b and 1d can be converted to the corresponding prodrug esters 1, R is --(CH2)2 N(R3)2 or --CH2 OOCR3, using known procedures. For example, treatment of 1d with a dilower alkylaminoethyl chloride (such as diethylaminoethyl chloride) or a chloromethyl lower alkanoate (such as chloromethyl acetate), in the presence of a tertiary amine, such as triethyl amine or N,N-diisopropylethylamine, in a solvent such as acetone or DMF at a temperature in the range from 25° to 80° gives the corresponding esters 1, R is --(CH2)2 N(R3)2 or --CH2 OOCR3 respectively.
In addition, the acids 1b and 1d can be converted to the esters 1a and 1c where R5 is lower alkyl by treatment with the corresponding lower alkyl halide, preferably the iodide, in the presence of an alkali metal bicarbonate in a solvent, such as, DMF at temperatures in the range of from 25° to 100°. ##STR7## R1 and p are as defined and Bn is benzyl
If R1 or R2 in 1d contain a benzyloxy substituent, such compounds (1e or 1g) can be converted to the corresponding hydroxy derivatives 1f and 1h, respectively according to Scheme 3. This can be accomplished by catalytic hydrogenolysis under the standard conditions described above.
The invention also relates to salts of the compounds of formula 1 when they contain an acidic functionality, such as when R is hydrogen, which lends itself to salt formation with a base. Salts of the compounds of formula 1 which have a carboxy group are prepared by the reaction with a base having a non-toxic, pharmacologically acceptable cation. In general, any base which will form a salt with a carboxylic acid and whose pharmacological properties will not cause an adverse physiological effect is within the scope of this invention.
Suitable bases thus include, for example, the alkali metal and alkaline earth metal hydroxides, carbonates or the like, for example, calcium hydroxide, sodium hydroxide, sodium carbonate, potassium carbonate or the like, ammonia, primary, secondary and tertiary amines, such as monoalkylamines, dialkylamines, trialkylamines, for example, methylamine, diethylamine, triethylamine or the like, nitrogen containing heterocyclic amines, for example, piperidine or the like. A salt thus produced is the functional equivalent of the corresponding compound of formula 1 wherein R is hydrogen and one skilled in the art will appreciate that the variety of salts embraced by the invention is limited only by the criterion that a base employed in forming the corresponding salts be both non-toxic and physiologically acceptable.
The useful activity of the compounds of formula 1 as phospholipase A2 (PLA2) inhibitors can be demonstrated as hereinafter set forth.
The compounds of formula 1 are potent inhibitors of phospholipases A2 (PLA2 's) and are therefore useful in the treatment of diseases, such as psoriasis, inflammatory bowel disease, asthma, allergy, arthritis, dermatitis, gout, pulmonary disease, myocardial ischemia, and trauma induced inflammation, such as spinal cord injury.
Assay for Inhibition of HSF-PLA2 In Vitro
The PLA2 used in this test is the extracellular enzyme obtained from human synovial fluid (HSF-PLA2).
The assay for HSF-PLA2 activity was a modification of the described method [Franson R., Dobrow R., Weiss, J., Elsbach P., and Weglick W. B., J. Lipid Res., 19, 18-23 (1978)] which was conducted using [1-14 C]-oleate-labelled E. coli substrate in excess at a final concentration of 20,000 dpm/ml. This was equivalent to 18.2 mM of cell membrane phospholipid phosphorus and 2×109 autoclaved E. coli/ml. The optimal conditions which were developed for the assay of HSF-PLA2 inhibitors are summarized as follows. A total volume of 0.5 ml of reaction mixture typically had the following final composition: substrate (20,000 dpm/ml); enzyme (0.1% HSF, v/v); 2 mM CaCl2 ; 150 mM Na+ ; 50 mM sodium HEPES buffer, pH 7.3; and 1% dimethyl sulfoxide (DMSO, used to solubilize test inhibitors) in the presence or absence of inhibitor. The reaction was initiated by the addition of HSF-PLA2 and duplicate samples of the mixture were incubated in 13×100 mm glass tubes with shaking for 30 minutes at 37° C. The reaction was terminated by the addition of 2.5 ml of chloroform-methanol (1 to 1.5, v/v). The extraction of lipids from the stopped reaction mixture was conducted by the further additions of 0.5 ml of chloroform and 1 ml of water with mixing. After centrifuging, the lower chloroform phase was transferred to smaller glass tubes and the solvent was evaporated to dryness with a nitrogen stream. The extracted lipid residue was redissolved in 50 ml of a solution containing carrier oleic acid (0.2 mg/ml) of chloroformmethanol [9 to 1, v/v]). The whole lipid extract was applied to a preactivated (30 minutes at 110° C.) silica gel-impregnated glass fiber thin layer chromatography sheet (ITLC type SG sheet from Gelman Sciences Inc., Ann Arbor, Mich.) using hexane-acetic acid (100 to 1, v/v) as the developing solvent. This TLC system rapidly (6 minutes) resolved the enzymatically released product, 14 C-oleic acid, from the unreacted 14 C-phospholipid substrate. The unsaturated lipids were located on the chromatogram by a brief exposure to iodine vapor. The oleic acid zone (Rf value 0.95) and phospholipid zone (origin) were cut out, chopped into small pieces, shaken with 2 ml of ethanol-water (80 to 20, v/v) and 15 ml of Aquasol and counted for radioactivity. A control incubation of substrate in the absence of HSF-PLA2 was performed in each experiment. The PLA2 activity of the human synovial fluid was corrected for this small control value. In the absence of inhibitors, these optimal conditions resulted in approximately 18% hydrolysis of substrate (corrected for a substrate blank of <2%). The specific activity of PLA2 in the pooled human synovial fluid under the optimal assay conditions was 49.2 nmoles [1-14 C]-oleic acid released hour-1 mg-1. The IC50 (μM concentration of test compound that produces 50% inhibition of PLA2 activity) was determined for each test compound. The results are reported in Tables I and II.
Croton Oil Mouse Ear Edema Test
The croton oil-induced mouse ear edema test, a model of irritant-induced contact dermatitis, has been used for evaluation of the PLA2 inhibitors by the topical route of administration. This test was carried out as described in the following references:
Weirich, E. G., Longauer, J. K and Kirkwood, A. A. Arch Dermatol. Res. 259: 141-149, 1977.
Tubaro, A., Dri, P., Delbello, G., Zilli, C. and Della Loggia, R. Agents and Actions, 17: 347-349, 1985.
The major active ingredient in croton oil is the tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA) and the topical application of TPA to mouse skin has been reported to cause an increase in epidermal PGE2 production as well as an increase in epidermal cell membrane PLA2 activity. Indomethacin, an inhibitor of prostaglandin synthesis, prevented the TPA-mediated increase in epidermal PGE2 levels as well as the TPA-mediated induction of epidermal cell ornithine decarboxylase. Furthermore, the application of PGE2 to mouse skin countered the inhibitory effect of indomethacin upon TPA-stimulated cellular proliferation. Taken together these data suggest that the croton oil mouse ear edema test is a valid model for the topical evaluation of PLA2 inhibitors.
Twenty five μl of a 1% croton oil solution [dissolved in a mixture of pyridine/water/diethyl ether at a ratio of 5/20/75 (croton oil vehicle)] are applied to the outer side of the right ear of 3-4 week old male CD-1 mice (8 animals per group). The test compounds are dissolved directly in the 1% croton oil solution at various concentrations and coapplied. Control animals receive 25 μl of croton oil vehicle on the right ear. Biopsy punches are removed at 6 hours from the fight ear of the animals using a 6 mm skin trephine (Roboz, Washington, D.C.) and the wet weight of the ear punches is determined. The weight of the biopsy punches is a measure of ear inflammation, primarily edema. The data are expressed as percent inhibition relative to control groups.
The in vivo activity of representative compounds of formula 1 in the croton oil ear edema test are reported in Table I.
Statistical analysis of the mean edema values of the control versus the treated groups is performed using Student's t-test. The significance of changes from the mean value for vehicle-treated (control) animals in the following Tables is indicated as follows: *p<0.05, **p<0.01, ***p<0.005, ns/not significant.
                                  TABLE I                                 
__________________________________________________________________________
                               % Inhib of                                 
                               Croton Oil                                 
                        % Inhib of                                        
                               Mouse Ear                                  
Ex No                                                                     
    Name                HSF-PLA.sub.2                                     
                               Edema (1 mg)                               
__________________________________________________________________________
 6  3,5-bis[3-(1,1'-biphenyl-4-yloxy)                                     
                        50                                                
                          (3 μM)                                       
                               NT                                         
    propoxy]benzoic acid                                                  
 8A 3,5-bis[2-(1-naphthalenyloxy)                                         
                        67                                                
                          (10 μM)                                      
                               NT                                         
    ethoxy]benzoic acid                                                   
11  3-(octadecyloxy)-5-(2,2-diphenyl-                                     
                        50                                                
                          (0.3 μM)                                     
                               71***                                      
    1-oxoethoxy)benzoic acid                                              
13  3-(octadecyloxy)-5-[(tricyclo[3.3.1./3,7/]                            
                        86                                                
                          (5 μM)                                       
                               81***                                      
    dec-1-ylcarbonyl)oxy]benzoic acid                                     
15  3-[2-(2-naphthalenyloxy)ethoxy]-                                      
                        77                                                
                          (10 μM)                                      
                               NT                                         
    5-(octadecyloxy)benzoic acid                                          
17  3-(octadecyloxy)-5-(3-phenoxy                                         
                        50                                                
                          (1.4 μM)                                     
                               81***                                      
    propoxy)benzoic acid                                                  
19  3-[[6-(2,3-dihydroxyphenyl)hexyl]oxy]-                                
                        50                                                
                          (1.1 μM)                                     
                               76***                                      
    5-(octadecyloxy)benzoic acid                                          
30  3-[[3-(4-phenylmethoxy)phenoxy]propoxy]-                              
                        NT     62***                                      
    5-(octadecyloxy)benzoic acid                                          
31  3-[3-(4-hydroxyphenoxy)propoxy]-                                      
                        37                                                
                          (1 μM)                                       
                               84***                                      
    5-(octadecyloxy)benzoic acid                                          
__________________________________________________________________________
TPA Induced Mouse Ear Edema Test
The TPA-induced mouse ear edema test, a model of irritant-induced contact dermatitis is described in the following reference: J. M. Young, B. M. Wagner and D. A. Spires, J. Invest. Dermatology 80, 48-52 (1983).
For this test, 10 μl of 12-O-tetradecanoylphorbol-13-acetate (TPA), dissolved in a vehicle of pyridine: water: diethyl ether (20:5:75), was applied to the outside of the right ear of 3-4 week old male CD-1 mice (8 animals per group). The test compounds were dissolved in the same vehicle and 10 μl was applied to the inside of the same ear 30 minutes prior to the application of TPA. Ear punches (6 mm) were removed at 6 hours after TPA application, weighed and assayed for myeloperoxidase (MPO) activity as described in the following reference: P. P. Bradley, D. A. Priebat, R. D. Christensen and G. Rothstein, J. Invest. Dermatology 78, 206-209 (1982). The wet weight of the ear biopsy punches is a measure of the ear edema and the level of MPO activity in the ear punches is an indicator of neutrophil infiltration. The data are expressed as percent inhibition of drug-treated animals relative to the control group.
The in vivo activity of representative compounds of formula 1 in the TPA mouse ear edema test is reported in Table II.
                                  TABLE II                                
__________________________________________________________________________
                                 % Inhib of                               
                                 TPA                                      
                          % Inhib of                                      
                                 Mouse Ear                                
Ex No                                                                     
    Name                  HSF-PLA.sub.2                                   
                                 Edema (1 mg)                             
__________________________________________________________________________
19  3-[[6-(2,3-dihydroxyphenyl)hexyl]oxy]-                                
                          50                                              
                            (1.1 μM)                                   
                                 55***                                    
    5-(octadecyloxy)benzoic acid (0.3 mg)                                 
24  3-[3-[4-(methylsulfinyl)phenoxy]propoxy]-                             
                          72                                              
                            (10 μM)                                    
                                 43***                                    
    5-(octadecyloxy)benzoic acid                                          
26  3-[3-[4-(methylsulfonyl)phenoxy]propoxy]-                             
                          86                                              
                            (10 μM)                                    
                                 42***                                    
    5-(octadecyloxy)benzoic acid                                          
31  3-[3-(4-hydroxyphenoxy)propoxy]-                                      
                          37                                              
                            (1 μM)                                     
                                 58***                                    
    5-(octadecyloxy)benzoic acid (0.3 mg)                                 
34  3-[3-(4-hydroxyphenoxy)propoxy]-5-                                    
                          2 (10 μM)                                    
                                 42***                                    
    (octadecyloxy)benzoic acid methyl ester                               
36  3-[3-[4-(phenylmethoxy)phenoxy]                                       
                          87                                              
                            (10 μM)                                    
                                 52**                                     
    propoxy]-5-(tetradecyloxy)benzoic acid                                
37  3-[3-(4-hydroxyphenoxy)propoxy]-                                      
                          75                                              
                            (10 μM)                                    
                                 57**                                     
    5-(tetradecyloxy)benzoic acid                                         
39  3-(decyloxy)-5-[3-[4-(phenylmethoxy)                                  
                          61                                              
                            (10 μM)                                    
                                 NT                                       
    phenoxy]propoxy]benzoic acid                                          
40  3-(decyloxy)-5-[3-(4-hydroxy                                          
                          50                                              
                            (8.8 μM)                                   
                                 58***                                    
    phenoxy)propoxy]benzoic acid (0.3 mg)                                 
41  3,5-bis[3-[4-(phenylmethoxy)                                          
                          54                                              
                            (10 μM)                                    
                                 54**                                     
    phenoxy]propoxy]benzoic acid                                          
42  3,5-bis[3-(4-hydroxyphenoxy)                                          
                          5 (10 μM)                                    
                                 43**                                     
    propoxy]benzoic acid                                                  
44  3-[[6-(4-hydroxyphenoxy)hexyl]                                        
                          94                                              
                            (10 μM)                                    
                                 46**                                     
    oxy]-5-(octadecyloxy)benzoic acid                                     
46  3-[3-(2-hydroxyphenoxy)propoxy]-                                      
                          91                                              
                            (10 μM)                                    
                                 47***                                    
    5-(octadecyloxy)benzoic acid (0.3 mg)                                 
49  5-(octadecyloxy)-2-[3-[4-(phenylmethoxy)                              
                          79                                              
                            (10 μM)                                    
                                 27**                                     
    phenoxy]propoxy]benzoic acid (0.3 mg)                                 
50  2-[3-(4-hydroxyphenoxy)propoxy]-                                      
                          93                                              
                            (10 μM)                                    
                                 45**                                     
    5-(octadecyloxy)benzoic acid                                          
53  4-(octadecyloxy)-2-[3-[4-(phenylmethoxy)                              
                          55                                              
                            (10 μM)                                    
                                 17 ns                                    
    phenoxy]propoxy]benzoic acid                                          
54  2-[3-(4-hydroxyphenoxy)propoxy]-                                      
                          79                                              
                            (10 μM)                                    
                                 31*                                      
    4-(octadecyloxy)benzoic acid                                          
57  3-(octadecyloxy)-2-[3-[4-(phenylmethoxy)                              
                          91                                              
                            (10 μM)                                    
                                 62***                                    
    phenoxy]propoxy]benzoic acid                                          
58  2-[3-(4-hydroxyphenoxy)propoxy]-                                      
                          93                                              
                            (10 μM)                                    
                                 48***                                    
    3-(octadecyloxy)benzoic acid (0.3 mg)                                 
61  3-[[6-(2,3-dihydroxyphenyl)hexyl]oxy]-5-                              
                          17                                              
                            (10 μM)                                    
                                 44***                                    
    (tetradecyloxy)benzoic acid methyl ester                              
63  3-[[6-(2,3-dihydroxyphenyl)hexyl]oxy]-                                
                          88                                              
                            (10 μM)                                    
                                 61***                                    
    5-(tetradecyloxy)benzoic acid                                         
                                 (0.3 mg)                                 
66  3-(decyloxy)-5-[[6-(2,3-dihydroxyphenyl)                              
                          22                                              
                            (10 μM)                                    
                                 55***                                    
    hexyl]oxy]benzoic acid methyl ester                                   
                            (0.3 mg)                                      
68  3-(decyloxy)-5-[[6-(2,3-dihydroxyphenyl)                              
                          74                                              
                            (20 μM)                                    
                                 58***                                    
    hexyl]oxy]benzoic acid  (0.3 mg)                                      
71  3-(decyloxy)-5-[[6-(2,3-dihydroxyphenyl)hexyl]                        
                          NT     57**                                     
    oxy]benzoic acid 2-(diethylamino)ethyl                                
    ester monohydrochloride salt                                          
72  3-(decyloxy)-5-[[6-(2,3-dihydroxyphenyl)hexyl]                        
                          NT     52***                                    
    oxy]benzoic acid (acetyloxy) methyl ester                             
                                 (0.1 mg)                                 
__________________________________________________________________________
The following representative compounds of the invention inhibited myeloperoxidase in the TPA mouse ear test when tested at 0.3 mg topically:
______________________________________                                    
Ex. No. Name                   % Inhib                                    
______________________________________                                    
19      3-[[6-(2,3-dihydroxyphenyl)hexyl]oxy]-                            
                               94                                         
        5-(octadecyloxy)benzoic acid                                      
31      3-[3-(4-hydroxyphenoxy)propoxy]-                                  
                               70                                         
        5-(octadecyloxy)benzoic acid                                      
40      3-(decyloxy)-5-[3-(4-hydroxy                                      
                               72                                         
        phenoxy)propoxy]benzoic acid                                      
58      2-[3-(4-hydroxyphenoxy)propoxy]                                   
                               62                                         
        3-(octadecyloxy)benzoic acid                                      
63      3-[[6-(2,3-dihydroxyphenyl)hexyl]oxy]-                            
                               61                                         
        5-(tetradecyloxy)benzoic acid                                     
68      3-(decyloxy)-5-[[6-(2,3-dihydroxy                                 
                               89                                         
        phenyl)hexyl]oxy]benzoic acid                                     
______________________________________
Phospholipase A2 Rat Paw Edema
Representative compounds of the invention were tested in rats to determine their ability to inhibit the acute inflammatory response induced by the injection of snake venom phospholipase A2. Test compounds were administered intraperitoneally or orally to groups of seven Lewis rats (˜200 gm) 1 hr prior to phospholipase A2 administration. The test compounds were dissolved in dimethyl sulfoxide for intraperitoneal administration and dissolved or suspended in Labrafil M-1944CS for oral administration. At 0 hr, 5 μg (10 units) of purified phospholipase A2 from Naja naja venom (Sigma Chem. Co.) dissolved in 0.1 mL of pyrogen free saline was injected subplantarly into the right hind paw to elicit the inflammatory response. The volume (in mL) of the fight hind paw was measured by immersion of the paw to the level of the lateral malleolus in an aqueous plethysmometer immediately prior to the injection of phospholipase A2 and then at 0.5, 2 and 4 hr after phospholipase A2 injection. The paw edema was calculated by subtracting the zero time reading from the readings taken after injection. The percent change of the edema volume from the vehicle treated control was calculated to determine the activity of the test compound.
An exemplary compound of the invention was tested:
3-(octadecyloxy)-5-(2,2-diphenyl-1-oxoethoxy)benzoic acid gave 29%* inhibition of edema measured 2 hours after PLA2 injection when tested at 30 mg/kg ip.
Rat Carrageenan Paw Edema
Representative compounds of the invention were tested in the rat carrageenan-induced paw edema test to determine their ability to inhibit this acute inflammatory response. Test compounds were administered intraperitoneally or orally to groups of seven Lewis rats (˜200 gm) 1 hr prior to carrageenan administration. The test compounds were dissolved in dimethyl sulfoxide for intraperitoneal administration and dissolved or suspended in Labrafil M-19944CS for oral administration. At 0 hour, 0.1 mL of 1% carrageenan dissolved in pyrogen free saline was injected subplantarly into the right hind paw to elicit the inflammatory response. The volume (in mL) of the right hind paw was measured by immersion of the paw to the level of the lateral malleolus in an aqueous plethysmometer immediately prior to the injection of carrageenan and then at 1, 2 and 4 hr after carrageenan injection. The paw edema was calculated by subtracting the zero time reading from the readings taken after injection. The percent change of the edema volume from the vehicle treated control was calculated to determine the activity of the test compound. Statistical analysis of the mean paw edema values of the control versus the treated groups was performed using Student's t-test.
3-[3-(4-hydroxyphenoxy)propoxy]-5-(octadecyloxy)benzoic acid, was tested at 30 mg/kg ip and gave 55%* inhibition of the edema measured at 2 hours after carrageenan injection.
Acetic Acid-Induced Colitis in Rats
The rat acetic acid-induced colitis bioassay has been described by J. E. Krawisz, et al. in Amer. J. Proc. Gastro. Col. Rec. Surg. 31:11-18 (1980), and by P. Sharon and W. F. Stenson in Gastroenterology 88, 55-63 (1985) and 86, 453-460 (1984). Acetic acid-induced colitis is characterized by the movement of inflammatory cells into the colon, ,with the number of such cells in the mucosa being measured by the activity of myeloperoxidase, a marker enzyme for these cells. Positive desirable activity is indicated by a reduction in the high levels of myeloperoxidase caused by acetic acid. Male rats (Sprague-Dawley), weighing 150 to 300 g, were pretreated twice daily for two days with either the vehicle (water or dimethylsulfoxide) or the test inhibitor compound suspended in water or dissolved in dimethylsulfoxide and orally administered. On the third day, the animals were dosed the same as on the previous two days, anesthetized with metofane, and 2 ml of 2.5% acetic acid was injected by syringe into the colonic lumen, followed immediately by 3 ml of air and a rinse consisting of 3 ml of phosphate-buffered saline (the acetic acid is present in the lumen for a sufficient period to cause inflammation without producing severe necrosis or irreversible damage). The animals were administered a second dose of the test compound in the same amount about 16 hours later. Then 24 hours after the acetic acid treatment, the animals were sacrificed. The colonic mucosa was surgically removed and homogenized in an aqueous buffer at pH 6 with a Tissumizer or similar device and myeloperoxidase was measured in the homogenate using o-phenylenediamine as a chromagen, as described by A. Voller, D. E. Bidwell and A. Bartlett in "The Enzyme Linked Immunosorbent Assay (ELISA)", Zoological Soc., London, 1979, pages 29-30. Control animals were pretreated with the vehicle and saline in place of acetic acid.
Data for a representative compound of the invention is reported below:
3-[[6-(2,3-Dihydroxyphenyl)hexyl]oxy]-5-(octadecyloxy)benzoic acid gave 56±17% inhibition of myeloperoxidase at a dose of 10 mg/kg orally.
In practice of the invention, the dose of a compound of formula 1 or a salt thereof to be administered and the frequency of administration will be dependent on the potency and duration of activity of the particular compound of formula 1 or salt to be administered and on the route of administration, as well as the severity and nature of the condition and age of the mammal to be treated and the like. Oral doses of a compound of formula 1 or a salt thereof contemplated for use in practicing the invention can be in the range of from 10 mg to about 2.0 g per day, preferably about 50 mg to about 1 g per day, either as a single dose or in divided doses. For topical use a compound of formula I or salt thereof contemplated for use in practicing the invention is present in the topical composition in the range of from about 1 to about 10%, preferably from about 2 to about 5%.
A compound of formula 1, or a salt or a composition containing a therapeutically effective amount of a compound of formula 1, or a salt thereof can be administered by methods well known in the art. Thus, a compound of formula 1, or a salt thereof can be administered either singly or with other pharmaceutical agents, for example, antihistamines, mediator release inhibitors, methyl xanthines, beta agonists or antiasthmatic steroids such as prednisone and prednisolone, orally, parenterally, rectally, or by inhalation, for example in the form of an aerosol, micropulverized powder or nebulized solution. For oral administration, they can be administered in the form of tablets, capsules, for example, in admixture with talc, starch, milk sugar or other inert ingredients, that is, pharmaceutically acceptable carriers, or in the form of aqueous solutions, suspensions, elixirs or aqueous alcoholic solutions, for example, in admixture with sugar or other sweetening agents, flavoring agents, colorants, thickeners and other conventional pharmaceutical excipients. For parenteral administration, they can be administered as solutions or suspension, for example, as an aqueous or peanut oil suspension using excipients and carriers conventional for this mode of administration. For administration as aerosols, they can be dissolved in a suitable pharmaceutically acceptable solvent, for example, ethyl alcohol or combinations of miscible solvents, and mixed with a pharmaceutically acceptable propellant. Such aerosol compositions are packaged for use in pressurized container fitted with an aerosol valve suitable for release of the pressurized composition. Preferably, the aerosol valve is a metered valve, that is one which on activation releases a predetermined effective dose of the aerosol composition. For topical use, they can conveniently be used in the form of salves, tinctures, creams, solutions, lotions, sprays, suspensions and the like. Salves and creams as well as solutions are preferred. These topical preparations can be prepared by mixing a compound of formula I as an active ingredient with one or more non-toxic, inert, solid or liquid carriers which are usual in such preparations and which are suitable for topical treatment.
EXPERIMENTAL SECTION
The Examples which follow further illustrate the invention. All temperatures set forth in the specification and the Examples are in degrees Centigrade. Melting points were taken on a Thomas Hoover capillary melting point apparatus and are uncorrected. All compounds were characterized by proton magnetic resonance spectra taken on a Varian XL-200 or XL-400 spectrometer and electron impact or fast atom bombardment mass spectra taken on either VG ZAB-1F or VG 70E-HF mass spectrometers. Preparative high-pressure liquid chromatography (HPLC) was performed on silica gel Prep-Pak 500 cartridges using a Waters Associates Prep LC 500A. Extracts were dried over anhydrous magnesium sulfate unless otherwise noted.
EXAMPLE 1 3,5-bis(3-Phenylpropoxy)benzoic acid methyl ester
A mixture of 1.68 g (0.01 mol) of 3,5-dihydroxybenzoic acid methyl ester, 3.4 mL (0.022 mol) of 3-bromopropylbenzene and 2.8 g (0.02 mol) of potassium carbonate in 50 mL of anhydrous DMF was stirred and heated at 100° for 18 hours. The solvent was removed at reduced pressure, the residue was acidified and the product was extracted with ethyl acetate. The dried extract was concentrated to dryness and the residue was purified by chromatography on 150 g of silica gel using 10 % ethyl acetate-hexane to give 3.0 g of 3,5-bis(3-phenylpropoxy)benzoic acid methyl ester as an oil. The nmr and mass spectra were consistent with the structure.
EXAMPLE 2 3,5-bis(3-Phenylpropoxy)benzoic acid
A solution of 3.0 g (7.4 mmol) of 3,5-bis(3-phenylpropoxy)benzoic acid methyl ester and 15 mL (15 mmol) of 1N NaOH in 100 mL of methanol and 40 mL of dioxane was stirred at reflux for 16 hours. The solvents were removed at reduced pressure, the residue was acidified and the product was extracted with ethyl acetate. The dried extract was concentrated to an oil which was crystallized from methanol-water to give 2.56 g, mp 107°-109°) of 3,5-bis(3-phenyl-propoxy)benzoic acid.
Anal. Calcd for C25 H26 O4 : C, 76.90; H, 6.71. Found: C, 76.42; H, 6.77.
EXAMPLE 3 4-(3-Bromopropoxy)-1,1-biphenyl
A mixture of 6 g (0.035 mol) of 4-phenylphenol, 11 mL (0.11 mol) of 1,3-dibromopropane and 7.5 g (0.054 mol) of potassium carbonate in 100 mL of acetone was stirred at reflux for 18 hours. The solvent was removed at reduced pressure and the residue was extracted with ethyl acetate. The extract was concentrated to a solid which was purified by HPLC using 10% ether-hexane to give 5.5 g, mp 60°-63°, of 4-(3-bromopropoxy)-1,1-biphenyl. The structure was confirmed by nmr and mass spectra.
EXAMPLE 4 3,5-bis[3-(1,1'-Biphenyl-4-yloxy)propoxy]benzoic acid methyl ester
A mixture of 0.79 g (4.7 mmol) of 3,5-dihydroxybenzoic acid methyl ester, 3.0 g (10.3 mmol) of 4-(3-bromopropoxy)-1,1-biphenyl, 1.55 g (10.3 mmol) of sodium iodide and 3.9 g (28 mmol) of potassium carbonate in 80 mL of anhydrous acetone and 40 mL of DMF was stirred at reflux for 39 hours. The solvents were removed at reduced pressure, water was added to the residue and the product was extracted with chloroform. The dried extract was concentrated to a solid which was purified by chromatography on 90 g of silica gel using chloroform to give 1.5 g (54% yield, mp 142°-145°) of 3,5-bis [3-(1,1'-biphenyl-4-yloxy)propoxy]benzoic acid methyl ester.
Anal. Calcd for C38 H36 O6 : C, 77.53; H, 6.16. Found: C. 77.48; H, 5.83.
EXAMPLE 5 A
Using this procedure, the reaction of 3,5-dihydroxybenzoic acid methyl ester with 2-(3-bromopropoxy)-1,1-biphenyl gave 3,5-bis[3-(1,1'-biphenyl-2-yloxy)propoxy]benzoic acid methyl ester, mp 77°-79°. Anal. Calcd for C38 H36 O6 : C, 77.53; H, 6.16. Found: C, 77.31; H, 6.15.
EXAMPLE 5 B
Using this procedure, the reaction of 3,5-dihydroxybenzoic acid methyl ester with 3-(3-bromopropoxy)-1,1-biphenyl gave 3,5-bis[3-(1,1'-biphenyl-3-yloxy)propoxy]benzoic acid methyl ester as an oil. The structure was confirmed by nmr and mass spectra.
EXAMPLE 6 3,5-bis[3-(1,1'-Biphenyl-4-yloxy)propoxy]benzoic acid
A solution of 1.5 g (2.55 mmol) of 3,5-bis[3-(1,1'-biphenyl-4-yloxy)propoxy]benzoic acid methyl ester and 15 mL (15 mmol) of 1N NaOH in 45 mL of methanol and 40 mL of dioxane was stirred at reflux for 6 hours. The reaction mixture was concentrated at reduced pressure, the residue was acidified and the product was filtered and recrystallized from ethyl acetate to give 1.3 g (89% yield, mp 186°-187°) of 3,5-bis[3-(1,1'-biphenyl-4-yloxy)propoxy]benzoic acid.
Anal. Calcd for C37 H34 O6 : C, 77.33; H, 5.96. Found: C, 77.28; H, 5.90.
EXAMPLE 6 A
Using this procedure, base hydrolysis of 3,5-bis[3-(1,1'-biphenyl-2-yloxy)propoxy]benzoic acid methyl ester gave 3,5-bis[3-(1,1'-biphenyl-2-yloxy)propoxy]benzoic acid, mp 110°-113°. The nmr and mass spectra were consistent with the structure.
EXAMPLE 6 B
Using this procedure, base hydrolysis of 3,5-bis[3-(1,1'-biphenyl-3-yloxy)propoxy]benzoic acid methyl ester gave 3,5-bis[3-(1,1'-biphenyl-3-yloxy)propoxy]benzoic acid, mp 65°-69°. The nmr and mass spectra were consistent with the structure.
EXAMPLE 7 3,5-bis[2-[2-(Naphthalenyloxy)ethoxy]benzoic acid methyl ester
A mixture of 0.90 g (5.3 mmol) of 3,5-dihydroxybenzoic acid methyl ester, 2.95 g (11.8 mmol) of 2-(2-bromoethoxy)naphthalene, 1.8 g (11.8 mmol) of sodium iodide and 3 g (21.7 mmol) of potassium carbonate in 80 mL of acetone and 25 mL of DMF was stirred at reflux for 40 hours. The solvents were removed at reduced pressure, water was added to the residue and the product was extracted with ethyl acetate. The dried extract was concentrated to a solid which was recrystallized from ethyl acetate to give 1.6 g (59% yield, mp 132°-137°) of 3,5-bis[2-[2-(naphthalenyloxy) ethoxy]benzoic acid methyl ester.
Anal. Calcd for C32 H28 O6 : C, 75.58; H, 5.55. Found: C, 75.19; H, 5.44.
EXAMPLE 7 A
Using this procedure, reaction of 3,5-dihydroxybenzoic acid methyl ester with 1-(2-bromoethoxy)naphthalene gave 3,5-bis[2-(1-naphthalenyloxy)ethoxy]benzoic acid methyl ester, mp 132°-137°, Anal. Calcd for C32 H28 O6 : C, 75.58; H, 5.55. Found: C, 75.19: H, 5.44.
EXAMPLE 8 3,5-bis[2-[2-(Naphthalenyloxy)ethoxy]benzoic acid
A solution of 1.6 g (3.15 mmol) of 3,5-bis[2-[2-(naphthalenyloxy) ethoxy]benzoic acid methyl ester and 15 mL (15 mmol) of 1N NaOH in 45 mL of methanol and 20 mL of dioxane was stirred at reflux for 2 hours. The usual workup followed by recrystallization from THF-ethyl acetate gave 1.2 g (77% yield, mp 205°-207°) of 3,5-bis[2-[2-(naphthalenyloxy)ethoxy]benzoic acid.
Anal. Calcd for C31 H26 O6 : C, 75.29; H, 5.30. Found: C, 74.60; H, 5.26.
EXAMPLE 8 A
Using this procedure, base hydrolysis of 3,5-bis[2-(1-naphthalenyloxy)ethoxy]benzoic acid methyl ester gave 3,5-bis[2-(1-naphthalenyloxy)ethoxy]benzoic acid, mp 213°-215°. Anal. Calcd for C31 H26 O6 : C, 74.29; H, 5.30. Found: C, 74.58; H, 5.36.
EXAMPLE 9 3-Hydroxy-5-(octadecyloxy)benzoic acid phenylmethyl ester
A mixture of 30 g (0.123 mol) of 3,5-dihydroxybenzoic acid phenylmethyl ester, 40.9 g (0.123 mol) of 1-bromooctadecane, 17 g (0.123 mol) of anhydrous potassium carbonate in 500 ml of acetone and 10 ml of DMF was stirred at reflux for 25 hours. The reaction mixture was filtered and the filtrate was concentrated at reduced pressure to a solid. The residue was treated with water and the product was extracted with methylene chloride. The dried extract was concentrated at reduced pressure to a solid which was purified by HPLC using 1% ethyl acetate-methylene chloride to give 22 g (36% yield, mp 72°-75°) of 3-hydroxy-5-(octadecyloxy)benzoic acid phenylmethyl ester. The structure was confirmed by nmr and mass spectra.
EXAMPLE 10 3-(Octadecyloxy)-5-(2,2-diphenyl-1-oxoethoxy)benzoic acid phenylmethyl ester
Diphenylacetyl chloride [from the reaction of 2.0 g (4.7 mmol) of diphenylacetic acid with thionyl chloride] dissolved in 20 ml of methylene chloride was added dropwise to an ice cooled solution of 2.0 g (4.0 mmol) of 3-hydroxy-5-(octadecyloxy)benzoic acid phenylmethyl ester and 1.1 ml (8 mmol) of triethylamine in 50 ml of methylene chloride with stirring. The reaction mixture was stirred with ice bath cooling for 1 hour, at room temperature for 20 hours and then was washed with 1N HCI and with NaHCO3 solution. After drying, the solvent was removed at reduced pressure and the crude product was purified by chromatography on 50 g of silica gel using 10% ethyl acetate-hexane to give 2.5 g, mp 47°-49°, of 3-(octadecyloxy)-5-(2,2-diphenyl-1-oxoethoxy)benzoic acid phenylmethyl ester. The nmr and mass spectra were consistent with the structure.
EXAMPLE 11 3-(Octadecyloxy)-5-(2,2-diphenyl-1-oxoethoxy) benzoic acid
A mixture of 2.5 g of 3-(octadecyloxy)-5-(2,2-diphenyl-1-oxoethoxy)benzoic acid phenylmethyl ester and 0.5 g of 10% palladium on carbon in 75 ml of THF was stirred under a hydrogen atmosphere until uptake ceased after 5 hours. The catalyst was removed by filtration and the filtrate was concentrated at reduced pressure to a solid which was recrystallized from methanol-water to give 2.0 g, mp 82°-86°, of 3-(octadecyloxy)-5-(2,2-diphenyl-1-oxoethoxy)benzoic acid.
Anal. Calcd for C39 H52 O5 : C, 77.96; H, 8.72. Found: C, 77.63; H, 8.79.
EXAMPLE 12 3-(Octadecyloxy)-5-[(tricyclo[3.3.1./3,7/]dec-1-ylcarbonyl)oxy]benzoic acid phenylmethyl ester
1-Adamantane carboxylic acid chloride (0.067 g) in 1 ml of methylene chloride was added to a stirred solution of 0.153 g of 3-hydroxy-5-(octadecyloxy)benzoic acid phenylmethyl ester and 0.09 ml of triethylamine in 10 ml of methylene chloride. The reaction mixture was stirred at room temperature for 17 hours and was then washed with 1N HCl and with NaHCO3 solution. After drying, the solvent was removed at reduced pressure and the crude product was purified by chromatography on 20 g of silica gel using 10% ethyl acetate-hexane to give 0.163 g of 3-(octadecyloxy)-5-[(tricyclo [3.3.1.1/3,7/]dec-1-ylcarbonyl)oxy]benzoic acid phenylmethyl ester as an oil. The nmr and mass spectra served to confirm the structure,
EXAMPLE 13 3-(Octadecyloxy)-5-[(tricyclo[3.3.1./3,7/]dec-1-ylcarbonyl)oxy]benzoic acid
A mixture of 0.16 g of 3-(octadecyloxy)-5-[(tricyclo[3.3.1./3,7/]dec-1-ylcarbonyl)oxy]benzoic acid phenylmethyl ester and 0.029 g of 10% palladium on carbon in 15 ml of THF was shaken under an initial hydrogen pressure of 54 psi in a Parr hydrogenator until uptake ceased after 2 hours. The usual workup followed by recrystallization from methanol-water gave 0.10 g, mp 44°-47°, of 3-(octadecyloxy)-5-[(tricyclo[3.3.1./3,7/]dec-1-ylcarbonyl)oxy]benzoic acid.
Anal. Calcd for C36 H56 O5 : C, 76.01; H, 9.92. Found: C, 76.15; H, 10.21.
EXAMPLE 14 3-[2-(2-Naphthalenyloxy)ethoxy]-5-(octadecyloxy) benzoic acid phenylmethyl ester
A mixture of 2.0 g (4 mmol) of 3-hydroxy-5-(octadecyloxy) benzoic acid phenylmethyl ester, 1.05 g 4.2 mmol) of 2-(2-bromoethoxy)naphthalene, 0.6 g (4 mmol) of sodium iodide and 1.1 g (8 mmol) of potassium carbonate in 60 ml of acetone and 15 ml of DMF was stirred at reflux for 49 hours. The solvents were removed at reduced pressure, water was added to the residue and the product was filtered. Recrystallization from methylene chloride-methanol gave 1.74 g, mp 62°-65°, of 3-[2-(2-naphthalenyloxy)ethoxy]-5-(octadecyloxy)benzoic acid phenylmethyl ester.
Anal. Calcd for C44 H58 O5 : C, 79.24; H, 8.77. Found: C, 78.90; H, 8.93.
EXAMPLE 15 3-[2-(2-Naphthalenyloxy)ethoxy]-5-(octadecyloxy) benzoic acid
A mixture of 1.74 g of 3-[2-(2-naphthalenyloxy)ethoxyl-5-(octadecyloxy)benzoic acid phenylmethyl ester and 1 g of 10% palladium on carbon was shaken under an initial hydrogen pressure of 54 psi in a Parr hydrogenator for 17 hours. The usual workup followed by recrystallization from methanol-water gave 1.18 g, mp 93°-94°, of 3-[2-(2-naphthalenyloxy)ethoxy]-5-(octadecyloxy)benzoic acid.
Anal. Calcd for C37 H52 O5 : C, 77.04; H, 9.09. Found: C, 76.81; H, 9.22.
EXAMPLE 16 3-(Octadecyloxy)-5-(3-phenoxypropoxy)benzoic acid phenylmethyl ester
A mixture of 12 g (0.024 mol) of 3-hydroxy-5-(octadecyloxy)-benzoic acid phenylmethyl ester, 6 ml (0.038 mol) of 3-phenoxy-propyl bromide, 3.6 g (0.024 mol) of sodium iodide and 10 g (0.072 mol) of potassium carbonate in 400 ml of acetone and 80 ml of DMF was stirred at reflux for 46 hours. The reaction mixture was filtered and the filtrate was concentrated to dryness at reduced pressure. Water was added to the residue and the product was extracted with ethyl acetate. The dried extract was concentrated at reduced pressure to an oil which was purified by HPLC using 5% ethyl acetate-hexane. The pure fractions were combined, triturated with hexane and filtered to give 14.6 g (96% yield, mp 46°-47°) of 3-(octadecyloxy)-5-(3-phenoxypropoxy)benzoic acid phenylmethyl ester. The structure was confirmed by nmr and mass spectra.
Anal. Calcd for C41 H58 O5 : C, 78.05; H, 9.27. Found: C, 77.89; H, 9.03.
EXAMPLE 17 3-(Octadecyloxy)-5-(3-phenoxypropoxy)benzoic acid
A mixture of 14.6 g of 3-(octadecyloxy)-5-(3-phenoxypropoxy) benzoic acid phenylmethyl ester and 3 g of 10% palladium on carbon was shaken in a hydrogen atmosphere at room temperature for 2 hours. The catalyst was removed by filtration and the filtrate was concentrated to a solid which was recrystallized from ether-hexane to give 11.8 g (95% yield, mp 79°-81°) of 3-(octadecyloxy)-5-(3-phenoxypropoxy)benzoic acid.
Anal. Calcd for C34 H52 O5 : C, 75.52; H, 9.69. Found: C, 75.09; H, 9.80.
EXAMPLE 18 3-[[6-[2,3-bis(Phenylmethoxy)phenyl]hexyl]oxy]-5-(octadecyloxy)benzoic acid phenylmethyl ester
A mixture of 1.5 g (3 mmol) of 3-hydroxy-5-(octadecyloxy) benzoic acid phenylmethyl ester, 1.6 g (3.4 mmol) of 1-(6-bromo-hexyl)-2,3-bis(phenylmethoxy)benzene [M. Carson, R.-J. Han and R. A. LeMahieu, U.S. Pat. No. 5,025,036 (1991)], 0.45 g (3 mmol) of potassium iodide and 0.84 g (6 mmol) of potassium carbonate in 40 ml of acetone and 10 ml of DMF was stirred at reflux for 47 hours. The solvents were removed at reduced pressure and the residue was purified by HPLC using 5% ethyl acetate-hexane to give 2.0 g (77% yield) of 3-[[6-[2,3-bis(phenylmethoxy)phenyl]hexyl]oxy]-5-(octadecyloxy)benzoic acid phenylmethyl ester as an oil. The nmr spectrum served to confirm the structure.
EXAMPLE 19 3-[[6-(2,3-Dihydroxyphenyl)hexyl]oxy]-5-(octadecyloxy) benzoic acid
A mixture of 2.0 g of 3-[[6-[2,3-bis(phenylmethoxy)phenyl]hexyl]oxy]-5-(octadecyloxy)benzoic acid phenylmethyl ester and 0.5 g of 10% palladium on carbon in 100 ml of THF was stirred in a hydrogen atmosphere until uptake ceased after 5 hours. The usual workup followed by trituration of the crude product with hexane gave 1.2 g (88% yield, mp 92°-94°) of 3-[[6-(2,3-dihydroxyphenyl) hexyl]oxy]-5-(octadecyloxy)benzoic acid.
Anal. Calcd for C37 H58 O6 : C, 74.21; H, 9.76. Found: C, 74.27; H, 9.55.
EXAMPLE 20 3-[(4-Methylthio)phenoxy]propyl bromide
A mixture of 10 g of 4-(methylmercapto)phenol, 72 ml of 1,3-dibromopropane and 30 g of potassium carbonate in 150 ml of acetone and 25 ml of DMF was stirred at reflux for 24 hours. The usual workup followed by purification by HPLC using 2% ethyl acetate-hexane gave 5.6 g (30% yield, mp 33°-35°) of 3-[(4-methyl-thio)phenoxy]propyl bromide.
Anal. Calcd for C10 H13 BrOS: C, 45.99; H, 5.02; Br, 30.59; S, 12.28. Found: C, 46.08; H, 4.89; Br, 30.86; S, 12.07.
EXAMPLE 21 3-[(4-Methylsulfinyl)phenoxy]propyl bromide
To 2.0 g (7.66 mmol) of 3-[(4-methylthio)phenoxy]propyl bromide in 100 ml of methanol a solution of 1.65 g (7.66 mmol) of sodium periodate in 10 ml of water was added dropwise over 10 minutes. The reaction mixture was stirred at room temperature for 4 days. The solvent was removed at reduced pressure, water was added to the residue and the product was extracted with ethyl acetate. The dried extract was concentrated to an oil which was triturated with hexane and filtered to give 1.93 g (91% yield, mp<30°) of 3-[(4-methylsulfinyl)phenoxy]propyl bromide.
Anal. Calcd for C10 H13 BrO2 S: C, 43.33; H, 4.73; Br, 28.83: S, 11.59. Found: C, 42.70; H, 4.74; Br, 28.81; S, 11.53.
EXAMPLE 22 3-[(4-Methylsulfonyl)phenoxy]propyl bromide
To 2.0 g (7.66 mmol) of 3-[(4-methylthio)phenoxy]propyl bromide in 75 ml of methylene chloride cooled in an ice bath was added in portions with stirring 2.9 g of 80% 3-chloroperbenzoic acid. After stirring at room temperature for 4 days, 1.5 g of 80% 3-chloroperbenzoic acid was added and stirring was continued for 24 hours. The reaction mixture was filtered and the filtrate was washed with NaHCO3 solution. The dried extract was concentrated to a solid which was recrystallized from ether-hexane to give 1.98 g (93% yield, mp 91°-93°) of 3-[(4-methylsulfonyl)phenoxy]propyl bromide.
Calcd for C10 H13 BrO3 S: C, 40.97; H, 4.47; Br, 27.26; S, 10.94; Found: C, 40.85; H, 4.38; Br, 27.56; S, 10.64.
EXAMPLE 23 3-[3-[4-(Methylsulfinyl)phenoxy]propoxy]-5-(octadecyloxy)benzoic acid methyl ester
A mixture of 0.8 g (1.9 mmol) of 3-hydroxy-5-(octadecyloxy) benzoic acid methyl ester, 0.63 g (2.28 mmol) of 3-[(4-methyl-sulfinyl)phenoxy]propyl bromide and 1 g (7.2 mmol) of potassium carbonate in 40 ml of acetone and 10 ml of DMF was stirred at reflux for 24 hours. The usual workup and recrystallization from ethyl acetate gave 0.8 g (68% yield, mp 86°-88°) of 3-[3-[4-(methylsulfinyl)phenoxy]propoxy]-5-(octadecyloxy)benzoic acid methyl ester.
Anal. Calcd for C36 H56 SO6 : C, 70.07; H, 9.15; S, 5.20. Found: C, 69.85; H, 9.24; S, 4.94.
EXAMPLE 24 3-[3-[4-(Methylsulfinyl)phenoxy]propoxy]-5-(octadecyloxy)benzoic acid
Sodium hydroxide hydrolysis of 3-[3-[4-(methylsulfinyl) phenoxy]propoxy]-5-(octadecyloxy)benzoic acid methyl ester as in earlier Examples gave 3-[3-[4-(methylsulfinyl)phenoxy]propoxy]-5-(octadecyloxy)benzoic acid (88% yield, mp 77°-80°).
Anal. Calcd for C35 H54 O6 S: C, 69.73; H, 9.03; S, 5.23. Found: C, 69.86; H, 9.20; S, 5.24.
EXAMPLE 25 3-[3-[4-(Methylsulfonyl)phenoxy]propoxy]-5-(octadecyloxy)benzoic acid methyl ester
A mixture of 0.8 g (1.9 mmol) of 3-hydroxy-5-(octadecyloxy) benzoic acid methyl ester, 0.668 g (2.28 mmol) of 3-[(4-methylsulfonyl)phenoxy]propyl bromide and 1 g (7.6 mmol) of potassium carbonate in 40 ml of acetone and 10 ml of DMF was stirred at reflux for 24 hours. The usual workup and recrystallization from ethyl acetate gave 1.1 g (92% yield, mp 101°-102°) of 3-[3-[4-(methylsulfonyl)phenoxy]propoxy]-5-(octadecyloxy)benzoic acid methyl ester.
Anal. Calcd for C36 H56 SO7 : C, 68.32; H, 8.92; S, 5.07. Found: C, 68.22; H, 9.12; S, 4.85.
EXAMPLE 26 3-[3-[4-(Methylsulfonyl)phenoxy]propoxy]-5-(octadecyloxy)benzoic acid
Sodium hydroxide hydrolysis of 3-[3-[4-(methylsulfonyl) phenoxy]propoxy]-5-(octadecyloxy)benzoic acid methyl ester as in earlier Examples gave 3-[3-[4-(methylsulfonyl)phenoxy]propoxy]-5-(octadecyloxy)benzoic acid (77% yield, mp 110°-111°).
Anal. Calcd for C35 H54 O7 S: C, 67.93; H, 8.80; S, 5.18. Found: C, 67.93; H, 8.90; S, 5.29.
EXAMPLE 27 3-Hydroxy-5-(octadecyloxy)benzoic acid methyl ester
A mixture of 5.0 g (0.03 mol) of 3,5-dihydroxybenzoic acid methyl ester, 9.9 g (0.03 mol) of 1-bromooctadecane and 4.1 g (0.03 mol) of potassium carbonate in 100 ml of acetone and 5 ml of DMF was stirred at reflux for 24 hours. The solvents were removed at reduced pressure and the residue was stirred with ethyl acetate and filtered to remove inorganic salts. The filtrate was concentrated to dryness and the residue was stirred with 500 ml of methylene chloride and filtered to remove the residual 3,5-dihydroxybenzoic acid methyl ester. The filtrate was concentrated and purified by chromatography on 300 g of silica gel using 5% ethyl acetate-toluene to give 4.07 g (33% yield, mp 93°-94°) of 3-hydroxy-5-(octadecyloxy) benzoic acid methyl ester.
EXAMPLE 28 3-[(4-Phenylmethoxy)phenoxy]propyl bromide
A mixture of 10 g (0.05 mol) of 4-benzyloxyphenol, 51 ml (0.5 mol) of 1,3-dibromopropane and 20.7 g (0.15 mol) of potassium carbonate in 150 ml of acetone was stirred at reflux for 24 hours. The solvent and excess 1,3-dibromopropane were removed at reduced pressure and the residue was crystallized from methanol to give 10 g (63% yield, mp 53°-56°) of 3-[(4-phenylmethoxy)phenoxy]propyl bromide.
EXAMPLE 29 3-[[3-(4-Phenylmethoxy)phenoxy]propoxy]-5-(octadecyloxy)benzoic acid methyl ester
A mixture of 4.0 g (9.5 mmol) of 3-hydroxy-5-(octadecyloxy) benzoic acid methyl ester, 3.05 g (9.5 mmol) 3-[(4-phenylmethoxy)phenoxy]propyl bromide, 1.43 g (9.5 mmol) of sodium iodide and 2.67 g (19 mmol) of potassium carbonate in 100 ml of acetone and 25 ml of DMF was stirred at reflux for 43 hours. The usual workup followed by recrystallization from methylene chloride gave 4.85 g (77% yield, mp 75°-77°) of 3-[[3-(4-phenylmethoxy) phenoxy]propoxy]-5-(octadecyloxy)benzoic acid methyl ester.
Anal. Calcd for C42 H60 O6 : C, 76.33; H, 9.15. Found: C, 76.04; H, 9.09.
EXAMPLE 30 3-[[3-(4-Phenylmethoxy)phenoxy]propoxy]-5-(octadecyloxy)benzoic acid
Sodium hydroxide hydrolysis of 3-[[3-(4-phenylmethoxy) phenoxy]propoxy]-5-(octadecyloxy)benzoic acid methyl ester gave 3-[[3-(4-phenylmethoxy)phenoxy]propoxy]-5-(octadecyloxy)benzoic acid (99% yield, mp 99°-101°)
Anal. Calcd for C41 H58 O6 : C, 76.12; H, 9.04. Found: C, 75.92; H, 9.02.
EXAMPLE 31 3-[3-(4-Hydroxyphenoxy)propoxy]-5-(octadecyloxy) benzoic acid
A mixture of 0.30 g of 3-[[3-(4-phenylmethoxy)phenoxy]propoxy]-5-(octadecyloxy)benzoic acid and 0.1 g of 10% palladium on carbon in 25 ml of THF was stirred in a hydrogen atmosphere until uptake ceased after 2 hours. The usual workup followed by recrystallization from ether-hexane gave 0.217 g (84% yield, mp 92°-95°) of 3-[3-(4-hydroxyphenoxy)propoxy]-5-(octadecyloxy)benzoic acid.
Anal. Calcd for C34 H52 O6 : C, 73.35; H, 9.41. Found: C, 73.07; H, 9.43
EXAMPLE 32 3-Hydroxy-5-[3-[4-(phenylmethoxy)phenoxy]propoxy]benzoic acid methyl ester
A mixture of 2.0 g (11.9 mmol) of 3,5-dihydroxybenzoic acid methyl ester, 3.8 g (11.9 mmol) of 3-[(4-phenylmethoxy)phenoxy]propyl bromide and 1.7 g (12.3 mmol) of potassium carbonate in 40 ml of acetone and 2 ml of DMF was stirred at reflux for 24 hours. The solvents were removed at reduced pressure, the residue was stirred with methylene chloride and filtered. The filtrate was concentrated to a solid which was recrystallized from methylene chloride-methanol to give 1.77 g, mp 134°-136°, of 3,5-bis[3-[4-(phenylmethoxy)phenoxy]propoxy]benzoic acid methyl ester. The filtrate was concentrated to a solid which was purified by chromatography on 20 g of silica gel (230-400 mesh) using 10% ethyl acetate-hexane to give 1.47 g (30% yield, mp 120°-122°) of 3-hydroxy-5-[3-[4-(phenylmethoxy)phenoxy]propoxy]benzoic acid methyl ester.
Anal. Calcd for C24 H24 O6 : C, 70.58; H, 5.92. Found: C, 70.86; H, 5.72.
EXAMPLE 33 3-(Octadecyloxy)-5-[3-[4-(phenylmethoxy)phenoxy]propoxy]benzoic acid methyl ester
A mixture of 11 g (27 mmol) of 3-hydroxy-5-[3-[4-(phenyl-methoxy)phenoxy]propoxy]benzoic acid methyl ester, 9.9 g (29.6 mmol) of 1-bromooctadecane and 7.5 g (55 mmol) of potassium carbonate in 225 ml of DMF was stirred and heated at 80° for 30 hours. The solvent was removed at reduced pressure and the residue was purified by chromatography on 300 g of silica gel using 10% ethyl acetate-hexane to give 15.7 g (88% yield, mp 76°-77°) of 3-(octadecyloxy)-5-[3-[4-(phenylmethoxy)phenoxy]propoxy]benzoic acid methyl ester.
EXAMPLE 34 3-[3-(4-Hydroxyphenoxy)propoxy]-5-(octadecyloxy) benzoic acid methyl ester
A mixture of 0.40 g of 3-(octadecyloxy)-5-[3-[4-(phenylmethoxy) phenoxy]propoxy]benzoic acid methyl ester and 0.1 g of 10% palladium on carbon in 25 ml of THF was stirred in a hydrogen atmosphere for 4 hours. The usual workup followed by purification by chromatography on 12 g of silica gel (230-400 mesh) using 20% ethyl acetate-hexane to give 0.177 g (51% yield, mp 85°-88°) of 3-[3-(4-hydroxyphenoxy)propoxy]-5-(octadecyloxy)benzoic acid methyl ester.
Anal. Calcd for C35 H54 O6 : C, 73.65; H, 9.54. Found: C, 73.81; H, 9.73.
EXAMPLE 35 3-[3-[4-(Phenylmethoxy)phenoxy]propoxy]-5-(tetradecyloxy)benzoic acid methyl ester
A mixture of 1.0 g (2.45 mmol) of 3-hydroxy-5-[3-[4-(phenylmethoxy)phenoxy]propoxy]benzoic acid methyl ester, 0.73 ml (2.69 mmol) of 1-bromotetradecane and 0.7 g (4.9 mmol) of potassium carbonate in 20 ml of anhydrous DMF was stirred and heated at 80° for 22 hours. The usual workup followed by chromatography on 30 g of silica gel using 10% ethyl acetate-hexane, trituration of the combined pure fractions with methanol and filtration gave 1.37 g (93% yield, mp 69°-70°) of 3-[3-[4-(phenylmethoxy)phenoxy]propoxy]-5-(tetradecyloxy)benzoic acid methyl ester.
EXAMPLE 36 3-[3-[4-(Phenylmethoxy)phenoxy]propoxy]-5-(tetradecyloxy)benzoic acid
Sodium hydroxide hydrolysis of 3-[3-[4-(phenylmethoxy) phenoxy]propoxy]-5-(tetradecyloxy)benzoic acid methyl ester gave 3-[3-[4-(phenylmethoxy)phenoxy]propoxy]-5-(tetradecyloxy)benzoic acid (96% yield, mp 77°-79°).
Anal. Calcd for C37 H50 O6 : C, 75.22; H, 8.53. Found: C, 74.90; H, 8.62.
EXAMPLE 37 3-[3-(4-Hydroxyphenoxy)propoxy]-5-(tetradecyloxy) benzoic acid
Catalytic hydrogenolysis of 3-[3-[4-(phenylmethoxy)phenoxy]propoxy]-5-(tetradecyloxy)benzoic acid as described in earlier Examples gave 3-[3-(4-hydroxyphenoxy)propoxy]-5-(tetradecyloxy) benzoic acid (92% yield, mp 91°-93°).
Anal. Calcd for C30 H44 O6 : C, 71.97; H, 8.86. Found: C, 72.08: H, 9.00.
EXAMPLE 38 3-(Decyloxy)-5-[3-[4-(phenylmethoxy)phenoxy]propoxy]benzoic acid methyl ester
A mixture of 1.0 g (2.45 mmol) of 3-hydroxy-5-[3-[4-(phenylmethoxy)phenoxy]propoxy]benzoic acid methyl ester, 0.6 ml (2.69 mmol) of 1-bromodecane and 0.7 g (4.9 mmol) of potassium carbonate in 20 ml of DMF was stirred at 80° for 24 hours. The usual workup followed by recrystallization from ether-hexane gave 1.25 g (93% yield, mp 68°-70°) of 3-(decyloxy)-5-[3-[4-(phenylmethoxy) phenoxy]propoxy]benzoic acid methyl ester.
EXAMPLE 39 3-(Decyloxy)-5-[3-[4-(phenylmethoxy)phenoxy]propoxy]benzoic acid
Sodium hydroxide hydrolysis of 3-(decyloxy)-5-[3-[4-(phenylmethoxy)phenoxy]propoxy]benzoic acid methyl ester gave 3-(decyloxy)-5-[3-[4-(phenylmethoxy)phenoxy]propoxy]benzoic acid (95% yield, mp 107°-109°)
Anal. Calcd for C33 H42 O6 : C, 74.13; H, 7.92. Found: C, 73.97; H, 8.16.
EXAMPLE 40 3-(Decyloxy)-5-[3-(4-hydroxyphenoxy)propoxy]benzoic acid
Catalytic hydrogenolysis of 3-(decyloxy)-5-[3-[4-(phenylmethoxy) phenoxy]propoxy]benzoic acid gave 3-(decyloxy)-5-[3-(4-hydroxyphenoxy)propoxy]benzoic acid (77% yield, mp 106°-109°).
Anal. Calcd for C26 H36 O6 : C, 70.24; H, 8.16. Found: C, 70.10; H, 8.14.
EXAMPLE 41 3,5-bis[3-[4-(Phenylmethoxy)phenoxy]propoxy]benzoic acid
A solution of 1.5 g (2.3 mmol) of 3,5-bis[3-[4-(phenylmethoxy) phenoxy]propoxy]benzoic acid methyl ester (prepared in Example 46) and 1.2 ml (7.2 mmol) of 6N NaOH in 25 ml of methanol and 10 ml of dioxane was stirred at reflux under argon for 19 hours. The solvents were removed at reduced pressure, the residue was acidified and the product was extracted with ethyl acetate. The dried extract was concentrated to a solid which was recrystallized from acetone-hexane to give 1.37 g (93% yield, mp 139°-140°) of 3,5-bis[3-[4-(phenylmethoxy)phenoxy]propoxy]benzoic acid.
Anal. Calcd for C39 H38 O8 : C, 73.80; H, 6.03. Found: C, 73.69; H, 6.20.
EXAMPLE 42 3,5-bis[3-(4-Hydroxyphenoxy)propoxy]benzoic acid
Catalytic hydrogenolysis under the usual conditions of 3,5-bis[3-[4-(phenylmethoxy)phenoxy]propoxy]benzoic acid gave 3,5-bis[3-(4-hydroxyphenoxy)propoxy]benzoic acid (94% yield, mp 160°-162°).
Anal. Calcd for C25 H26 O8 : C, 66.07; H, 5.77. Found: C, 65.94; H, 5.64.
EXAMPLE 43 3-(Octadecyloxy)-5-[[6-[4-(phenylmethoxy)phenoxy]hexyl]oxy]benzoic acid phenylmethyl ester
A mixture of 0.60 (1.2 mmol) of 3-hydroxy-5-(octadecyloxy) benzoic acid phenylmethyl ester, 0.46 g (1.27 mmol) of 6-[(4-phenylmethoxy)phenoxy]hexyl bromide and 0.3 g (2.17 mmol) of potassium carbonate in 20 ml of acetone and 1 ml of DMF was stirred at reflux for 21 hours. The usual workup followed by chromatography on 40 g of silica gel (230-400 mesh) using 5% ethyl acetate-hexane gave 0.7 g (74% yield, mp 60°-62°) of 3-(octadecyloxy)-5-[[6-[4-(phenylmethoxy)phenoxy]hexyl]oxy]benzoic acid phenylmethyl ester.
EXAMPLE 44 3-[[6-(4-Hydroxyphenoxy)hexyl]oxy]-5-(octadecyloxybenzoic acid
Catalytic hydrogenolysis of 3-(octadecyloxy)-5-[[6-[4-(phenylmethoxy)phenoxy]hexyl]oxy]benzoic acid phenylmethyl ester gave 3-[[6-(4-hydroxyphenoxy)hexyl]oxy]-5-(octadecyloxybenzoic acid, mp 104°-105°.
Anal. Calcd for C37 H58 O6 : C, 74.21; H, 9.76. Found: C, 74.24; H, 9.98.
EXAMPLE 45 3-(Octadecyloxy)-5-[3-[2-(phenylmethoxy)phenoxy]propoxy]benzoic acid phenylmethyl ester
A mixture of 0.6 g (1.2 mmol) of 3-hydroxy-5-(octadecyloxy) benzoic acid phenylmethyl ester, 0.3 g (2.17 mmol) of 3-[(2-phenylmethoxy)phenoxy]propyl bromide and 0.3 g (2.17 mmol) of potassium carbonate in 20 ml of acetone and 1 ml of DMF was stirred at reflux for 23 hours. The usual workup followed by chromatography on 40 g of silica gel (230-400 mesh) using 5% ethyl acetate-hexane gave 0.6 g (67% yield, mp 49°-50°) of 3-(octadecyloxy)-5-[3-[2-(phenylmethoxy)phenoxy]propoxy]benzoic acid phenylmethyl ester.
EXAMPLE 46 3-[3-(2-Hydroxyphenoxy)propoxy]-5-(octadecyloxy) benzoic acid
Catalytic hydrogenolysis of 3-(octadecyloxy)-5-[3-[2-(phenylmethoxy)phenoxy]propoxy]benzoic acid phenylmethyl ester gave 3-[3-(2-hydroxyphenoxy)propoxy]-5-(octadecyloxy)benzoic acid, mp 75°-77°.
Anal. Calcd for C34 H52 O6 : C, 73.35; H, 9.41. Found: C, 73.16; H, 9.66.
EXAMPLE 47 2-Hydroxy-5-(octadecyloxy)benzoic acid methyl ester
A mixture of 1 g (5.95 mmol) of 2,5-dihydroxybenzoic acid methyl ester, 1.98 g (5.95 mmol) of 1-bromooctadecane and 0.825 g (5.95 mmol) of potassium carbonate in 20 ml of acetone and 1 ml of DMF was stirred at reflux for 20 hours. The usual workup followed by purification by HPLC using 1% ethyl acetate-hexane gave 1.8 (72% yield, mp 61°-64°) of 2-hydroxy-5-(octadecyloxy)benzoic acid methyl ester.
EXAMPLE 48 5-(Octadecyloxy)-2-[3-[4-(phenylmethoxy)phenoxy]propoxy]benzoic acid methyl ester
A mixture of 1 g (2.4 mmol) of 2-hydroxy-5-(octadecyloxy) benzoic acid methyl ester, 0.85 g (2.6 mmol) of 3-[(4-phenylmethoxy)phenoxy]propyl bromide and 0.65 g (4.7 mmol) of potassium carbonate in 40 ml of acetone and 7 ml of DMF was stirred at reflux for 48 hours. The usual workup followed by recrystallization from ethyl acetate-hexane gave 1.2 g (76% yield, mp 81°-83°) of 5-(octadecyloxy)-2-[3-[4-(phenylmethoxy)phenoxy]propoxy]benzoic acid methyl ester.
Anal. Calcd for C42 H60 O6 : C, 76.12; H, 9.04. Found: C, 75.96; H, 9.23.
EXAMPLE 49 5-(Octadecyloxy)-2-[3-[4-(phenylmethoxy)phenoxy]propoxy]benzoic acid
Hydrolysis with sodium hydroxide of 5-(octadecyloxy)-2-[3-[4-(phenylmethoxy)phenoxy]propoxy]benzoic acid methyl ester gave 5-(octadecyloxy)-2-[3-[4-(phenylmethoxy)phenoxy]propoxy]benzoic acid, mp 93°-95°.
Anal. Calcd for C41 H58 O6 : C, 76.12; H, 9.04. found: C, 75.96; H, 9.23.
EXAMPLE 50 2-[3-(4-Hydroxyphenoxy)propoxy]-5-(octadecyloxy) benzoic acid
Catalytic hydrogenolysis of 5-(octadecyloxy)-2-[3-[4-(phenylmethoxy)phenoxy]propoxy]benzoic acid gave 2-[3-(4-hydroxyphenoxy)propoxy]-5-(octadecyloxy)benzoic acid, mp 98°-100°.
Anal. Calcd for C34 H52 O6 : C, 73.35; H, 9.41. Found: C, 73.16; H, 9.42.
EXAMPLE 51 2-Hydroxy-4-(octadecyloxy)benzoic acid methyl ester
A mixture of 1 g (5.95 mmol) of 2,4-dihydroxybenzoic acid methyl ester, 1.98 g (5.95 mmol) of 1-bromooctadecane and 0.825 g (5.95 mmol) of potassium carbonate was stirred at reflux for 40 hours in 20 ml of acetone and 2 ml of DMF. The usual workup followed by purification by HPLC using 1% ethyl acetate-hexane gave 2-hydroxy -4-(octadecyloxy)benzoic acid methyl ester, mp 61°-64°.
EXAMPLE 52 4-(Octadecyloxy)-2-[3-[4-(phenylmethoxy)phenoxy]propoxy]benzoic acid methyl ester
A mixture of 1 g (2.4 mmol) of 2-hydroxy-4-(octadecyloxy) benzoic acid methyl ester, 0.9 g (2.8 mmol) of 3-[(4-phenylmethoxy) phenoxy]propyl bromide and 1.2 g (8.7 mmol) of potassium carbonate in 40 ml of acetone and 10 ml of DMF was stirred at reflux for 44 hours. The usual workup followed by chromatography on 30 g of silica gel using 10% ethyl acetate-hexane gave 1.3 g, mp 68°-70°, of 4-(octadecyloxy)-2-[3-[4-(phenylmethoxy)phenoxy]propoxy]benzoic acid methyl ester.
EXAMPLE 53 4-(Octadecyloxy)-2-[3-[4-(phenylmethoxy)phenoxy]propoxy]benzoic acid
Sodium hydroxide hydrolysis of 4-(octadecyloxy)-2-[3-[4-(phenylmethoxy)phenoxy]propoxy]benzoic acid methyl ester gave 4-(octadecyloxy)-2-[3-[4-(phenylmethoxy)phenoxy]propoxy]benzoic acid (88% yield, mp 102°-104°).
Anal. Calcd for C41 H58 O6 : C, 76.12; H, 9.04. Found: C, 76.08; H, 9.16.
EXAMPLE 54 2-[3-(4-Hydroxyphenoxy)propoxy]-4-(octadecyloxy) benzoic acid
Catalytic hydrogenolysis of 4-(octadecyloxy)-2-[3-[4-(phenylmethoxy)phenoxy]propoxy]benzoic acid gave 2-[3-(4-hydroxyphenoxy)propoxy]-4-(octadecyloxy)benzoic acid (62% yield, mp 97°-100°).
Anal. Calcd for C34 H52 O6 : C, 73.35; H, 9.41. Found: C, 73.40; H, 9.54.
EXAMPLE 55 2-Hydroxy-3-(octadecyloxy)benzoic acid methyl ester
A mixture of 1.0 g (5.95 mmol) of 2,3-dihydroxybenzoic acid methyl ester, 1.98 g (5.95 mmol) of 1-bromooctadecane and 0.825 g (5.95 mmol) of potassium carbonate in 20 ml of acetone and 4 ml of DMF was stirred at reflux for 40 hours. The usual workup followed by purification by chromatography on 40 g of silica gel (230-400 mesh) using 50% toluene-hexane gave 0.40 g (16% yield, mp 57°-60°) of 2-hydroxy-3-(octadecyloxy)benzoic acid methyl ester. The structure was established by nmr and mass spectra.
EXAMPLE 56 3-(Octadecyloxy)-2-[3-[4-(phenylmethoxy)phenoxy]propoxy]benzoic acid methyl ester
A mixture of 0.40 g (0.95 mmol) of 2-hydroxy-3-(octadecyloxy) benzoic acid methyl ester, 0.365 g (1.14 mmol) of 3-[(4-phenylmethoxy)phenoxy]propyl bromide and 0.60 g 4.35 mmol) of potassium carbonate in 20 ml of acetone and 5 ml of DMF was stirred at reflux for 44 hours. The usual workup followed by chromatography on 30 g of silica gel (230-400 mesh) using 10% ethyl acetate-hexane gave 0.50 g (79% yield, mp 43°-45°) of 3-(octadecyloxy)-2-[3-[4-(phenylmethoxy)phenoxy]propoxy]benzoic acid methyl ester.
EXAMPLE 57 3-(Octadecyloxy)-2-[3-[4-(phenylmethoxy)phenoxy]propoxy]benzoic acid
Sodium hydroxide hydrolysis of 3-(octadecyloxy)-2-[3-[4-(phenylmethoxy)phenoxy]propoxy]benzoic acid methyl ester gave 3-(octadecyloxy)-2-[3-[4-(phenylmethoxy)phenoxy]propoxy]benzoic acid (76% yield, mp 75°-76°).
Anal. Calcd for C41 H58 O6 : C, 76;12; H, 9.04. Found: C, 75.88; H. 9.25.
EXAMPLE 58 2-[3-(4-Hydroxyphenoxy)propoxy]-3-(octadecyloxy) benzoic acid
Catalytic hydrogenolysis of 3-(octadecyloxy)-2-[3-[4-(phenylmethoxy)phenoxy]propoxy]benzoic acid gave 2-[3-(4-hydroxyphenoxy)propoxy]-3-(octadecyloxy)benzoic acid (77% yield, mp 81°-83°).
Anal. Calcd for C34 H52 O6 : C, 73.35; H, 9.441. Found: C, 73.27; H, 9.47.
EXAMPLE 59 3-Hydroxy-5-(tetradecyloxy)benzoic acid methyl ester
A mixture of 10 g (0.06 mol) of 3,5-dihydroxybenzoic acid methyl ester, 16.2 ml (0.06 mol) of 1-bromotetradecane and 8.2 g (0.06 mol) of potassium carbonate in 200 ml of acetone and 20 ml of DMF was stirred at reflux under argon for 24 hours, After the usual workup, the crude product was triturated with hot methylene chloride and filtered. The filtrate was concentrated at reduced pressure and the solid residue was recrystallized from methylene chloride-methanol to give the 3,5-dialkylated product. The filtrate was concentrated and the residue was purified by HPLC using 15% ethyl acetatehexane to give 7.3 g (34% yield, mp 92°-94°) of 3-hydroxy-5-(tetradecyloxy)benzoic acid methyl ester. The nmr spectra was consistent with the structure.
EXAMPLE 60 3-[[6-[2,3-bis(Phenylmethoxy)phenyl]hexyl]oxy]-5-(tetra-decyloxy)benzoic acid methyl ester
A mixture of 1.5 g (4.1 mmol) of 3-hydroxy-5-(tetradecyloxy) benzoic acid methyl ester, 2.3 g (5.1 mmol) of 1-(6-bromohexyl)-2,3-bis(phenylmethoxy)benzene, 1.1 g (8.2 mmol) of potassium carbonate and 0.6 g (4.1 mmol) of sodium iodide in 50 ml of acetone and 15 ml of DMF was stirred at reflux under argon for 32 hours. After the usual workup, the crude product was crystallized from methylene chloride-methanol to give 2.8 g (93% yield, mp 56°-58°) of 3-[[6-[2,3-bis(phenylmethoxy)phenyl]hexyl]oxy]-5-(tetradecyloxy) benzoic acid methyl ester.
Anal. Calcd for C48 H64 O6 : C, 78.22; H, 8.75. Found: C, 77.99; H, 8.66.
EXAMPLE 61 3-[[6-(2,3-Dihydroxyphenyl)hexyl]oxy]-5-(tetradecyloxy) benzoic acid methyl ester
A mixture of 1.0 g of 3-[[6-[2,3-bis(phenylmethoxy)phenylhexyl]oxy]-5-(tetradecyloxy)benzoic acid methyl ester and 0.4 g of 10% palladium on carbon in 100 ml of THF was stirred in a hydrogen atmosphere until uptake ceased after 3.5 hours. After the usual workup, the crude product was triturated with hexane and filtered to give 0.65 g (86% yield, mp 77°-79°) of 3-[[6-(2,3-dihydroxyphenyl) hexyl]oxy]-5-(tetradecyloxy)benzoic acid methyl ester.
Anal. Calcd for C34 H52 O6 : C, 73.35; H, 9.41. Found: C, 73.53; H, 9.29.
EXAMPLE 62 3-[[6-[2,3-bis(Phenylmethoxy)phenyl]hexyl]oxy]-5-(tetradecyloxy)benzoic acid
A solution of 1.78 g (2.3 mmol) of 3-[[6-[2,3-bis(phenylmethoxy) hexyl]oxy]-5-(tetradecyloxy)benzoic acid methyl ester and 1.2 ml (7.2 mmol) of 6N NaOH in 75 ml of methanol and 25 ml of dioxane was stirred at reflux under argon for 20 hours. After the usual workup, 1.67 g (mp 75°-77°), of 3-[[6-[2,3-bis(phenylmethoxy) phenyl]hexyl]oxy]-5-(tetradecyloxy)benzoic acid was obtained.
EXAMPLE 63 3-[[6-(2,3-dihydroxyphenyl)hexyl]oxy]-5-(tetradecyloxy)benzoic acid
A mixture of 1.66 g of 3-[[6-[2,3-bis(phenylmethoxy)phenyl]hexyl]oxy]-5-(tetradecyloxy)benzoic acid and 0.3 g of 10% palladium on carbon in 75 ml of THF was stirred in a hydrogen atmosphere until uptake ceased after 4 hours. The usual workup followed by trituration with hexane and filtration gave 1.14 g (91% yield, mp 92°-94°) of 3-[[6-(2,3-dihydroxyphenyl)hexyl]oxy]-5-(tetradecyloxy) benzoic acid.
Anal. Calcd for C33 H50 O6 : C, 73.03; H, 9.29. Found: C, 73.05; H, 9.21.
EXAMPLE 64 3-(Decyloxy)-5-hydroxybenzoic acid methyl ester
A mixture of 10.0 g (0.06 mol) of 3,5-dihydroxybenzoic acid methyl ester, 12.3 ml (0.06 mol) of 1-bromodecane and 8.2 g (0.06 mol) of potassium carbonate in 200 ml of acetone and 20 ml of DMF was stirred at reflux under argon for 24 hours. After the usual workup, purification by HPLC using 15% ethyl acetate-hexane gave 7.3 g (34% yield, mp 92°-94°) of 3-(decyloxy)-5-hydroxybenzoic acid methyl ester. The nmr spectra was consistent with the structure.
EXAMPLE 65 3-(Decyloxy)-5-[[6-[2,3-bis(phenylmethoxy)phenyl]hexyl]oxy]benzoic acid methyl ester
A mixture of 1.5 g (4.86 mmol) of 3-(decyloxy)-5-hydroxybenzoic acid methyl ester, 2.2 g (4.86 mmol) of 1-(6-bromohexyl)-2,3-bis (phenylmethoxy)benzene, 1.3 g (9.7 mmol) of potassium carbonate and 0.73 g (4.86 mmol) of sodium iodide in 50 ml of acetone and 15 ml of DMF was stirred at reflux for 48 hours. After the usual workup, the crude product was purified by HPLC using 10% ethyl acetate-hexane to give 2.47 g (75% yield, mp 45°-46°) of 3-(decyloxy)-5-[[6-[2,3-bis(phenylmethoxy)phenyl]hexyl]oxy]benzoic acid methyl ester.
Anal. Calcd for C44 H56 O6 : C, 77.61; H, 8.29. Found: C, 77.68; H, 8.41.
EXAMPLE 66 3-(Decyloxy)-5-[[6-(2,3-dihydroxyphenyl)hexyl]oxy]benzoic acid methyl ester
A mixture of 0.7 g of 3-(decyloxy)-5-[[6-[2,3-bis(phenylmethoxy) phenyl]hexyl]oxy]benzoic acid methyl ester and 0.3 g of 10% palladium on carbon was stirred in a hydrogen atmosphere until uptake ceased after 4.5 hours. After the usual workup, the crude product was triturated with hexane and filtered to give 0.45 g (87% yield, mp 71°-72°) of 3-(decyloxy)-5-[[6-(2,3-dihydroxyphenyl) hexyl]oxy]benzoic acid methyl ester.
Anal. Calcd for C30 H44 O6 : C, 71.97; H, 8.86. Found: C, 71.97; H, 9.03.
EXAMPLE 67 3-(Decyloxy)-5-[6-[[2,3-bis(phenylmethoxy)phenyl ]hexyl]oxy]benzoic acid
A solution of 1.75 g (2.57 mmol) of 3-(decyloxy)-5-[[6-[2,3-bis (phenylmethoxy)phenyl]hexyl]oxy]benzoic acid methyl ester and 1.3 ml (7.8 mmol) of 6N NaOH in 75 ml of methanol and 25 ml of dioxane was stirred at reflux under argon for 24 hours. The usual workup gave 3-(decyloxy)-5-[[6-[2,3-bis(phenylmethoxy)phenyl]hexyl]oxy]benzoic acid. The nmr and mass spectra were consistent with the structure.
EXAMPLE 68 3-(Decyloxy)-5-[[6-(2,3-dihydroxyphenyl)hexyl]oxy]benzoic acid
A mixture of 1.7 g of 3-(decyloxy)-5-[[6-[2,3-bis(phenylmethoxy) phenyl]hexyl]oxy]benzoic acid and 0.3 g of 10% palladium on carbon in 75 ml of THF was stirred in a hydrogen atmosphere until uptake ceased after 2.5 hours. The usual workup followed by trituration of the crude product from hexane and filtration gave 1.13 g (91% yield, mp 86°-88°) of 3-(decyloxy)-5-[[6-(2,3-dihydroxyphenyl)hexyl]oxy]benzoic acid.
Anal. Calcd for C29 H42 O6 : C, 71.58; H, 8.70. Found: C, 71.70; H, 8.72.
EXAMPLE 69 3-[[6-(2,3-Dihydroxyphenyl)hexyl]oxy]-5-(octadecyloxy) benzoic acid methyl ester
A mixture of 0.15 g (0.25 mmol) of 3-[[6-(2,3-dihydroxyphenyl) hexyl]oxy]-5-(octadecyloxy)benzoic acid, 0.05 g (0.6 mmol) of sodium bicarbonate and 0.64 ml (10 mmol) of methyl iodide in 3 ml of DMF was stirred and heated at 40° for 5 days. An additional 0.32 ml of methyl iodide and 0.05 g of sodium bicarbonate were added and heating at 40° was continued for 6 days. The solvent was removed at reduced pressure, the residue was extracted with ethyl acetate and the extract was washed with water. The dried extract was concentrated to an oil which was purified by chromatography on 4 g of silica gel using 25% ethyl acetate-hexane to give 0.104 g (68% yield, mp 82°-84°) of 3-[[6-(2,3-dihydroxyphenyl)hexyl]oxy]-5-(octadecyloxy)benzoic acid methyl ester.
Anal. Calcd for C36 H60 O6 : C, 74.47; H, 9.87. Found: C, 74.35: H, 9.82.
EXAMPLE 70 3-[3-(4-Hydroxyphenoxy)propoxy]-5-(octadecyloxy) benzoic acid methyl ester
A mixture of 0.30 g (0.54 mmol) of 3-[3-(4-hydroxyphenoxy) propoxy]-5-(octadecyloxy)benzoic acid, 0.14 g (1.62 mmol) of sodium bicarbonate and 0.67 ml (10.8 mmol) of methyl iodide in 5 ml of DMF was stirred and heated at 40° for 48 hours. The solvent was removed at reduced pressure, the residue was extracted with ethyl acetate and the extract was washed with water. The dried extract was concentrated to a solid which was triturated with hexane and filtered to give 0.298 g (97% yield, mp 88°-90°) of 3-[3-(4-hydroxyphenoxy)propoxy]-5-(octadecyloxy)benzoic acid methyl ester.
Anal. Calcd for C35 H54 O6 : C, 73.63; H, 9.54. Found: C, 73.44; H, 9.45.
EXAMPLE 71 3-(Decyloxy)-5-[[6-(2,3-dihydroxyphenyl)hexyl]oxy]benzoic acid 2-(diethylamino)ethyl ester monohydrochloride salt
To 0.5 g (0.75 mmol) of 3-(decyloxy)-5-[[6-[2,3-bis(phenylmethoxy)phenyl]hexyl]oxy]benzoic acid in 20 ml of DMF stirred under argon and heated at 80° was added dropwise a solution of 0.2 g (1.5 mmol) of 2-diethylaminoethyl chloride in 5 ml of DMF. The reaction mixture was stirred and heated at 80° for 3 hours when an additional 0.2 g of 2-diethylaminoethyl chloride was added. Heating was continued at 80° for 45 hours and the solvent was then removed at reduced pressure. Saturated NaHCO3 solution was added to the residue and the product was extracted with ethyl acetate. The dried extract was concentrated to a yellow oil which was purified by chromatography on 40 g of 230-400 mesh silica gel using 50% ethyl acetate-hexane to give 0.25 g (44% yield) of 3-(decyloxy)-5-[[6-[2,3-bis(phenylmethoxy)phenyl]hexyl]oxy]benzoic acid 2-(diethylamino) ethyl ester as an oil. A mixture of 0.25 g of 3-(decyloxy)-5-[[6-[2,3-bis(phenylmethoxy)phenyl]hexyl]oxy]benzoic acid 2-(diethylamino) ethyl ester and 0.1 g of 10% palladium on carbon in 15 ml of THF was stirred at room temperature under a hydrogen atmosphere for 5 hours when uptake ceased. The usual workup gave the free base of the title compound which was dissolved in methylene chloride and treated with 0.32 ml of 3N HCl in ethanol. The solvents were removed at reduced pressure, the residue was triturated with ether and the product was removed by filtration to give 0.13 g, mp 88°-91°, of 3-(decyloxy)-5-[[6-(2,3-dihydroxyphenyl)hexyl]oxy]benzoic acid 2-(diethylamino)ethyl ester monohydrochloride salt.
Anal. Calcd for C35 H55 NO6.1:1 HCl: C, 67.56; H, 9.07; N, 2.25; Cl-, 5.70. Found: C, 67.57; H, 8.94; 2.17; Cl- 5.50.
EXAMPLE 72 3-(Decyloxy)-5-[[6-(2,3-dihydroxyphenyl)hexyl]oxy]benzoic acid (acetyloxy)methyl ester
A mixture of 0.5 g (0.75 mmol) of 3-(decyloxy)-5-[[6-[2,3-bis (phenylmethoxy)phenyl]hexyl]oxy]benzoic acid, 0.25 g (2.25 mmol) of chloromethyl acetate, 0.23 g (1.5 mmol) of sodium iodide and 0.31 ml (2.25 mmol) of triethylamine in 15 ml of acetone and 5 ml of DMF was stirred at reflux under argon for 19 hours. The solvent was removed under reduced pressure, NaHCO3 solution was added to the residue and the product was extracted with ethyl acetate. The dried extract was concentrated to an oil which was purified by HPLC using 10% ethyl acetate-hexane to give 0.13 g of 3-(decyloxy)-5-[[6-[2,3-bis(phenylmethoxy)phenyl]hexyl]oxy]benzoic acid (acetyloxy)methyl ester as an oil. A mixture of 0.13 g of 3-(decyloxy)-5-[[6-[2,3-bis (phenylmethoxy)phenyl]hexyl]oxy]benzoic acid (acetyloxy)methyl ester and 0.1 g of 10% palladium on carbon in 15 ml of ethyl acetate was stirred under a hydrogen atmosphere for 3.5 hours when uptake ceased. The usual workup gave 0.07 g of 3-(decyloxy)-5-[[6-(2,3-dihydroxyphenyl)hexyl]oxy]benzoic acid (acetyloxy) methyl ester as an oil. The structure was confirmed by the nmr and mass spectra.
__________________________________________________________________________
EXAMPLE 73                                                                
TABLET FORMULATION (Wet Granulation)                                      
Item                                                                      
   Ingredients  5 mg                                                      
                   10 mg                                                  
                       25 mg                                              
                           100 mg                                         
                               250 mg                                     
                                   500 mg                                 
__________________________________________________________________________
1. Compound A*   5 10  25  100 250.0                                      
                                   500                                    
2. Lactose Anhydrous DTG                                                  
                125                                                       
                   120 105 30  75.0                                       
                                   150                                    
3. Pregelatinized Starch                                                  
                 6  6   6   6  15.0                                       
                                    30                                    
4. Microcrystalline Cellulose                                             
                30 30  30  30  75.0                                       
                                   150                                    
5. Magnesium Stearate                                                     
                 1  1   1   1   2.5                                       
                                    5                                     
   Total        167                                                       
                   167 167 167 417.5                                      
                                   835                                    
__________________________________________________________________________
 *3-[[6(2,3-dihydroxyphenyl)hexyl]oxy5-(octadecyloxy)benzoic acid         

__________________________________________________________________________
EXAMPLE 74                                                                
TABLET FORMULATION (Wet Granulation)                                      
Item                                                                      
   Ingredients                                                            
             5 mg                                                         
                 10 mg                                                    
                      25 mg                                               
                          100 mg                                          
                              250 mg                                      
                                   500 mg                                 
__________________________________________________________________________
1. Compound A*                                                            
             5   10   25  100 250.0                                       
                                   500                                    
2. Corn Starch                                                            
             103 98   83  8   20.0   403.3                                
3. Modified Starch                                                        
             4   4    4   4   10.0  20                                    
4. Talc      4   4    4   4   10.0  20                                    
5. Magnesium Stearate                                                     
             1   1    1   1    2.5  5                                     
   Total     117 117  117 117 292.5                                       
                                   585                                    
__________________________________________________________________________

______________________________________                                    
EXAMPLE 75                                                                
o/w Cream, 5%                                                             
Ingredients         % by Wt.                                              
______________________________________                                    
Compound A          5.0                                                   
Petrolatum (and) Lanolin                                                  
                    5.0                                                   
(and) Lanolin Alcohol                                                     
Isodecyl Oleate     1.0                                                   
Octyl Palmitate     1.0                                                   
Disopropyl Adipate  1.0                                                   
Cetearyl Alcohol (and)                                                    
                    5.0                                                   
Ceteareth 20 (Promulgen D)                                                
Cetyl Alcohol       1.0                                                   
Stearyl Alcohol     1.0                                                   
Steareth -10 (Brij 76)                                                    
                    1.0                                                   
Steareth -20 (Brij 78)                                                    
                    1.0                                                   
Purified Water      74.0                                                  
Preservatives       q.s.                                                  
______________________________________
1. Heat the petrolatum, lanolin, and lanolin alcohol mixture isodecyl oleate, octyl palmitate, diisopropyl adipate, cetearyl alcohol and ceteareth 20 mixture, cetyl alcohol, stearyl alcohol, steareth -10 and steareth 20° to 70°-80° C. Mix until all components have melted and are dissolved.
2. Heat the purified water to 70°-80° C. Add water soluble preservatives to the heated water and mix until dissolved.
3. Add the oil soluble preservatives to the lipid phase (Step 1). Mix until dissolved.
4. Dissolve the drug in the lipid phase from Step 3. Mix vigorously until the drug is dissolved.
5. Add Step 2 to Step 4. Homogenize until a uniform emulsion is formed.
6. Continue stirring the emulsion and cool to room temperature.
______________________________________                                    
EXAMPLE 76                                                                
Hydrophilic Ointment 5%                                                   
Ingredients        % by Wt.                                               
______________________________________                                    
Compound A         5.0                                                    
Petrolatum (and) Lanolin                                                  
                   10.0                                                   
Alcohol (Amerchol CAB)                                                    
Isopropyl Lanolate 5.0                                                    
(Amerlate P)                                                              
Petrolatum         25.0                                                   
Cetyl Alcohol      2.0                                                    
Stearyl Alcohol    2.0                                                    
Steareth -10       2.0                                                    
(Brij -76)                                                                
Steareth -20       2.0                                                    
(Brij -78)                                                                
Methyl Gluceth -20 5.0                                                    
(Glucam E-20)                                                             
Purified Water     42.0                                                   
Preservatives      q.s.                                                   
______________________________________
1. Heat the petrolatum and lanolin alcohol mixture isopropyl lanolate, petrolatum, cetyl alcohol, stearyl alcohol, steareth -10, steareth -20 and methyl glyceth -20° to 70°, 80° C. Mix until all components have melted and are dissolved.
2. Heat the purified water to 70°-80° C. Add water soluble preservatives to the heated water and mix until dissolved.
3. Add the oil soluble preservatives to the lipid phase of Step 1. Mix until dissolved.
4. Dissolve the drug in the lipid phase from Step 3. Mix vigorously until the drug is dissolved.
5. Add Step 2 to Step 4. Homogenize until a uniform emulsion is formed.
6. Continue stirring the emulsion and cool to room temperature.
______________________________________                                    
EXAMPLE 77                                                                
Ointment (Anhydrous) 5.0%                                                 
Ingredients        % by wt.                                               
______________________________________                                    
Compound A          5.0                                                   
White Petrolatum   38.0                                                   
Mineral Oil, 70 vis.                                                      
                   10.0                                                   
Sorbitan Sesquioleate                                                     
                    5.0                                                   
(Arlacel 83)                                                              
Petrolatum (and) Lanolin                                                  
                   15.0                                                   
Alcohol (Amerchol CAB)                                                    
Isopropyl Lanolate  6.0                                                   
(Amerlate P)                                                              
Mineral Oil (and) Lanolin                                                 
                   10.0                                                   
Alcohol (Amerchol L101)                                                   
Acetylated Lanolin 10.0                                                   
(Modulan)                                                                 
Paraffin Wax        2.0                                                   
Preservative       q.s.                                                   
______________________________________
1. Heat white petrolatum, mineral oil, sorbitan sesquioleate, petrolatum and lanolin alcohol mixture, isopropyl lanolate, mineral oil and lanolin alcohol mixture, acetylated lanolin and paraffin wax to 70°-80° C. Mix until all components have melted and are dissolved.
2. Cool the mixture from Step 1 to 50° C. and add the preservatives. Mix until dissolved.
3. Add the drug to Step 2. Mix vigorously until drug is dissolved.
4. Cool Step 3 to room temperature with stirring.

Claims (30)

We claim:
1. A compound of the formula ##STR8## R is hydrogen, lower alkyl, --(CH2)2 N(R3)2 or --CH2 OOCR3 wherein R3 is lower alkyl;
R1 is CH3 (CH2)n --, wherein n is 9-17, or R4 (CH2)p --, wherein p is 3-10 and R4 is 1- or 2-naphthyloxy, 2,3- or 3,4-dihydroxyphenyl, phenyl, phenoxy, or substituted phenyl or phenoxy wherein the substituent is selected from the group consisting of hydroxy, benzloxy, methylsulfinyl, methylsulfonyl or phenyl;
R2 is R4 (CH2)p --, 1-adamantyl--CO-- or diphenylmethyl--CO--, and, where R is hydrogen or a pharmaceutically acceptable salt with a base.
2. A compound, in accordance with claim 1, wherein the substitution pattern is: ##STR9##
3. A compound in accordance with claim 1, wherein the substitution pattern is 1,3,5 or 1,2,3;
R1 is CH3 (CH2)n --, wherein n is 9-17;
R2 is 1-adamantyl--CO--, diphenylmethyl--CO--, or R4 (CH2)p--, wherein p is 3-10 and R4 is 2,3- or 3,4-dihydroxyphenyl or substituted phenoxy wherein the substituent is selected from hydroxy or benzyloxy or methylsulfinyl.
4. A compound in accordance with claim 1, wherein the substitution pattern is 1,3,5;
R1 is CH3 (CH2)n --, wherein n is 9-17;
R2 is R4 (CH2)p --, wherein p is 3-8 and R4 is 2,3-dihydroxyphenyl or substituted phenoxy wherein the substituent is selected from benzyloxy or hydroxy; and R is hydrogen.
5. A compound in accordance with claim 1, 3-[[6-(2,3-dihydroxyphenyl)hexyl]oxy]-5-(octadecyloxy)benzoic acid.
6. A compound in accordance with claim 1, 3-[3-(4-hydroxyphenoxy)propoxy]-5-(octadecyloxy)benzoic acid.
7. A compound in accordance with claim 1, 3-[3-(4-hydroxyphenoxy)propoxy]-5-(tetradecyloxy)benzoic acid.
8. A compound in accordance with claim 1, 3-(decyloxy)-5-[3-(4-hydroxyphenoxy)propoxy]benzoic acid.
9. A compound in accordance with claim 1, 3-[[6-(2,3-dihydroxyphenyl)hexyl]oxy]-5-(tetradecyloxy)benzoic acid.
10. A compound in accordance with claim 1, 3-(decyloxy)-5-[[6-(2,3-dihydroxyphenyl)hexyl]oxy]benzoic acid.
11. A pharmaceutical composition comprising a compound of the formula ##STR10## R is hydrogen, lower alkyl, --(CH2)2 N(R3)2 or --CH2 OOCR3 wherein R3 is lower alkyl;
R1 is CH3 (CH2)n --, wherein n is 9-17, or R4 (CH2)p --, wherein p is 2-18 and R4 is 1- or 2-naphthyloxy, 2,3- or 3,4-dihydroxyphenyl, phenyl, phenoxy, or substituted phenyl or phenoxy wherein the substituent is selected from the group consisting of hydroxy, benzyloxy, methylsulfinyl, methylsulfonyl or phenyl;
R2 is R4 (CH2)p --, 1-adamantyl--CO-- or diphenylmethyl--CO--, and, when R is hydrogen or a pharmaceutically acceptable salt thereof with a base and an inert carrier.
12. A pharmaceutical composition, in accordance with claim 11, wherein the compound of formula I has the substitution pattern: ##STR11##
13. A pharmaceutical composition, in accordance with claim 11, wherein the compound of formula I has the substitution pattern of 1,3,5 or 1,2,3;
R1 is CH3 (CH2)n --, wherein n is 9-17;
R2 is 1-adamantyl--CO--, diphenylmethyl--CO--, or R4 (CH2)p --, wherein p is 3-10 and R4 is 2,3- or 3,4-dihydroxyphenyl or substituted phenoxy wherein the substituent is selected from hydroxy or benzyloxy or methylsulfinyl and R is as defined.
14. A pharmaceutical composition, in accordance with claim 11, wherein the compound of formula I has the substitution pattern of 1,3,5;
R1 is CH3 (CH2)n --, wherein n is 9-17;
R2 is R4 (CH2)p --, wherein p is 3-8 and R4 is 2,3-dihydroxyphenyl or substituted phenoxy wherein the substituent is selected from benzyloxy, hydroxy, nitro or amino; and R is hydrogen.
15. A pharmaceutical composition in accordance with claim 11, 3-[[6-(2,3-dihydroxyphenyl)hexyl]oxy]-5-(octadecyloxy)benzoic acid.
16. A pharmaceutical composition in accordance with claim 11, 3-[3-(4-hydroxyphenoxy)propoxy]-5-(octadecyloxy)benzoic acid.
17. A pharmaceutical composition in accordance with claim 11, 3-[3-(4-hydroxyphenoxy)propoxy]-5-(tetradecyloxy)benzoic acid.
18. A pharmaceutical composition in accordance with claim 11, 3-(decyloxy)-5-[3-(4-hydroxyphenoxy)propoxy]benzoic acid.
19. A pharmaceutical composition in accordance with claim 11, 3-[[6-(2,3-dihydroxyphenyl)hexyl]oxy]-5-(tetradecyloxy)benzoic acid.
20. A method of inhibiting phospholipases A2 which comprises administering to a host requiring such treatment an effective amount of a compound of the formula ##STR12## R is hydrogen, lower alkyl, --(CH2)2 N(R3)2 or --CH2 OOCR3 wherein R3 is lower alkyl;
R1 is CH3 (CH2)n --, wherein n is 9-17, or R4 (CH2)p --, wherein p is 3-10 and R4 is 1- or 2-naphthyloxy, 2,3- or 3,4-dihydroxyphenyl, phenyl, phenoxy, or substituted phenyl or phenoxy wherein the substituent is selected from the group consisting of hydroxy, benzyloxy, methylsulfinyl, methylsulfonyl or phenyl;
R2 is R4 (CH2)p --, 1-adamantyl--CO-- or diphenylmethyl--CO--, and, when R is hydrogen or a pharmaceutically acceptable salt with a base.
21. A method of treating psoriasis which comprises administering to a host requiring such treatment an effective amount of a compound of the formula ##STR13## R is hydrogen, lower alkyl, --(CH2)2 N(R3)2 or --CH2 OOCR3 wherein R3 is lower alkyl;
R1 is CH3 (CH2)n --, wherein n is 9-17, or R4 (CH2)p --, wherein p is 3-10 and R4 is 1- or 2-naphthyloxy, 2,3- or 3,4-dihydroxyphenyl, phenyl, phenoxy, or substituted phenyl or phenoxy wherein the substituent is selected from the group consisting of hydroxy, benzyloxy, methylsulfinyl, methylsulfonyl or phenyl;
R2 is R4 (CH2)p --, 1-adamantyl--CO-- or diphenylmethyl--CO--, and, when R is hydrogen or a pharmaceutically acceptable salt with a base.
22. A method of treating dermatitis which comprises administering to a host requiring such treatment an effective amount of a compound of the formula ##STR14## R is hydrogen, lower alkyl, --(CH2)2 N(R3)2 or --CH2 OOCR3 wherein R3 is lower alkyl;
R1 is CH3 (CH2)n --, wherein n is 9-17, or R4 (CH2)p --, wherein p is 3-10 and R4 is 1- or 2-naphthyloxy, 2,3- or 3,4-dihydroxyphenyl, phenyl, phenoxy, or substituted phenyl or phenoxy wherein the substituent is selected from the group consisting of hydroxy, benzyloxy, methylsulfinyl, methylsulfonyl or phenyl;
R2 is R4 (CH2)p --, 1-adamantyl--CO-- or diphenylmethyl--CO--, and, when R is hydrogen or a pharmaceutically acceptable salt thereof with a base.
23. A method, in accordance with claim 20, wherein the compound of formula 1 has the substitution pattern: ##STR15##
24. A method, in accordance with claim 20, wherein the compound of formula 1 has the substitution pattern of 1,3,5 or 1,2,3;
R1 is CH3 (CH2)n --, wherein n is 6-17;
R2 is 1-adamantyl--CO--, diphenylmethyl--CO--, or R4 (CH2)p --, wherein p is 3-10 and R4 is 2,3- or 3,4-dihydroxyphenyl or substituted phenoxy wherein the substituent is selected from hydroxy, benzyloxy, methoxy, nitro, amino or methylsulfinyl.
25. A method, in accordance with claim 20, wherein the compound of formula I has the substitution pattern of 1,3,5;
R1 is CH3 (CH2)n --, wherein n is 9-17; R2 is R4 (CH2)p --, wherein p is 3-8 and R4 is 2,3-dihydroxyphenyl or substituted phenoxy wherein the substituent is benzyloxy or hydroxy; and R is hydrogen.
26. A method in accordance with claim 20, 3-[[6-(2,3-dihydroxyphenyl)hexyl]oxy]-5-(octadecyloxy)benzoic acid.
27. A method in accordance with claim 20, 3-[3-(4-hydroxyphenoxy)propoxy]-5-(octadecyloxy)benzoic acid.
28. A method in accordance with claim 20, 3-[3-(4-hydroxyphenoxy)propoxy]-5-(tetradecyloxy)benzoic acid.
29. A method in accordance with claim 20, 3-(decyloxy)-5-[3-(4-hydroxyphenoxy)propoxy]benzoic acid.
30. A method in accordance with claim 20, 3-[[6-(2,3-dihydroxyphenyl)hexyl]oxy]-5-(tetradecyloxy)benzoic acid.
US08/141,309 1992-12-08 1993-10-22 Substituted benzoic acids, inhibitors of phospholipases A2 Expired - Fee Related US5374772A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US08/141,309 US5374772A (en) 1992-12-08 1993-10-22 Substituted benzoic acids, inhibitors of phospholipases A2

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98722792A 1992-12-08 1992-12-08
US08/141,309 US5374772A (en) 1992-12-08 1993-10-22 Substituted benzoic acids, inhibitors of phospholipases A2

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US98722792A Continuation-In-Part 1992-12-08 1992-12-08

Publications (1)

Publication Number Publication Date
US5374772A true US5374772A (en) 1994-12-20

Family

ID=25533130

Family Applications (1)

Application Number Title Priority Date Filing Date
US08/141,309 Expired - Fee Related US5374772A (en) 1992-12-08 1993-10-22 Substituted benzoic acids, inhibitors of phospholipases A2

Country Status (8)

Country Link
US (1) US5374772A (en)
EP (1) EP0601385A1 (en)
JP (1) JPH06211743A (en)
CN (1) CN1092059A (en)
AU (1) AU5195693A (en)
CA (1) CA2110116A1 (en)
NZ (1) NZ250336A (en)
ZA (1) ZA938988B (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004009528A1 (en) * 2002-07-18 2004-01-29 J. Uriach Y Compañia S.A. 2,4-dihydroxybenzoic acid derivatives
WO2007039111A3 (en) * 2005-09-20 2007-06-14 Revotar Biopharmaceuticals Ag Novel multi-cyclic compounds and their use
WO2008020026A1 (en) * 2006-08-16 2008-02-21 Action Medicines, S.L. Use of 2,5-dihydroxybenzene derivatives for treating dermatitis
WO2008020042A1 (en) * 2006-08-16 2008-02-21 Action Medicines, S.L. Use of 2, 5-dihydroxybenzene derivatives for the treatment of tissue reactive diseases
US20080207639A1 (en) * 2005-09-20 2008-08-28 Revotar Biopharmaceuticals Ag Novel Aromatic Compounds and Their Use in Medical Applications
US20080207741A1 (en) * 2005-09-20 2008-08-28 Revotar Biopharmaceuticals Ag Novel Hydroxylated Aromatic Compounds
US20080249107A1 (en) * 2004-03-18 2008-10-09 Revotar Biopharmaceuticals Ag Non-Glycosylated/Non-Glycosidic/Non-Peptidic Small Molecule Psgl-1 Mimetics for the Treatment of Inflammatory Disorders
US20090105280A1 (en) * 2005-09-20 2009-04-23 Revotar Biopharmaceuticals Ag Novel Aromatic Nitro Compounds
US8436045B2 (en) 2004-02-17 2013-05-07 AmDerma Pharmaceuticals, LLC Use of 2,5-dihydroxybenzene derivatives for treating actinic keratosis
US8435971B2 (en) 2004-02-17 2013-05-07 AmDerma Pharmaceuticals, LLC Use of 2,5-dihydroxybenzenesulfonic acid in the manufacturing of medicines, applicable to the treatment of angiodependent diseases
US8497257B2 (en) 2004-02-17 2013-07-30 AmDerma Pharmaceuticals, LLC Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and psoriasis

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2315118B1 (en) * 2006-08-16 2009-12-30 Action Medicines, S.L. USE OF 2,5-DIHYDROXIBENCENIC COMPOUNDS AND DERIVATIVES IN THE PREPARATION OF USEFUL MEDICINES IN THE TREATMENT OF ROSACEA AND PSORIASIS.
ES2315117B1 (en) * 2006-08-16 2009-12-30 Action Medicines, S.L. USE OF 2,5-DIHYDROXIBENCENIC DERIVATIVES IN THE PREPARATION OF USEFUL MEDICATIONS IN THE TREATMENT OF ASTHMA.
JP6812112B2 (en) * 2016-02-25 2021-01-13 上野製薬株式会社 Method for Purifying 4-Hydroxybenzoic Acid Long Chain Ester

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3078314A (en) * 1959-12-15 1963-02-19 Minnesota Mining & Mfg Polyunsaturated phenyl ethers and their preparation
DE2439458A1 (en) * 1973-08-23 1975-02-27 Beecham Group Ltd MEDICINAL PRODUCTS, NEW COMPOUNDS AND PROCEDURES FOR THEIR MANUFACTURING CONTAINED IN THESE PRODUCTS
EP0068250A1 (en) * 1981-06-26 1983-01-05 Bayer Ag Dioxybenzene ether derivatives, pharmaceutical compositions containing them, process for the preparation thereof and their use
US4499295A (en) * 1983-05-09 1985-02-12 G. D. Searle & Co. Protease inhibitors
US4670465A (en) * 1986-05-21 1987-06-02 Syntex (U.S.A.) Inc. Arachidonic acid analogs
EP0310126A2 (en) * 1987-10-01 1989-04-05 F. Hoffmann-La Roche Ag Derivatives of pyrocatechol-carboxylic acid, their preparation and use as active ingredients in medicines
US4871712A (en) * 1988-09-08 1989-10-03 The United States Of America As Represented By The Secretary Of The Air Force Decyloxy-substituted terephthalic acid compounds and method of synthesis
US5025036A (en) * 1987-10-01 1991-06-18 Hoffmann-La Roche Inc. Catechol carboxylic acids

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3078314A (en) * 1959-12-15 1963-02-19 Minnesota Mining & Mfg Polyunsaturated phenyl ethers and their preparation
DE2439458A1 (en) * 1973-08-23 1975-02-27 Beecham Group Ltd MEDICINAL PRODUCTS, NEW COMPOUNDS AND PROCEDURES FOR THEIR MANUFACTURING CONTAINED IN THESE PRODUCTS
EP0068250A1 (en) * 1981-06-26 1983-01-05 Bayer Ag Dioxybenzene ether derivatives, pharmaceutical compositions containing them, process for the preparation thereof and their use
US4590291A (en) * 1981-06-26 1986-05-20 Bayer Aktiengesellschaft Thrombin inhibitory new dihydroxybenzene ether derivatives
US4499295A (en) * 1983-05-09 1985-02-12 G. D. Searle & Co. Protease inhibitors
US4670465A (en) * 1986-05-21 1987-06-02 Syntex (U.S.A.) Inc. Arachidonic acid analogs
EP0310126A2 (en) * 1987-10-01 1989-04-05 F. Hoffmann-La Roche Ag Derivatives of pyrocatechol-carboxylic acid, their preparation and use as active ingredients in medicines
US5025036A (en) * 1987-10-01 1991-06-18 Hoffmann-La Roche Inc. Catechol carboxylic acids
US4871712A (en) * 1988-09-08 1989-10-03 The United States Of America As Represented By The Secretary Of The Air Force Decyloxy-substituted terephthalic acid compounds and method of synthesis

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
Franson R; Dobrow R; Weiss J; Elsbach P; and Weglick W. B., J. Lipid Res. 19, 18 23 (1978). *
Franson R; Dobrow R; Weiss J; Elsbach P; and Weglick W. B., J. Lipid Res. 19, 18-23 (1978).
J. E. Krawisz et al., In Amer. J. Proc. Gastro. Col. Rec. Surg. 31; 11 18 (1980). *
J. E. Krawisz et al., In Amer. J. Proc. Gastro. Col. Rec. Surg. 31;-11-18 (1980).
J. M. Yound; B. M. Wagner & D. A. Spires J. Invest. Dermatology 80, 48 52 (1983). *
J. M. Yound; B. M. Wagner & D. A. Spires J. Invest. Dermatology 80, 48-52 (1983).
P. P. Bradley; D. A. Priebat, R. D. Christensen & G. Rothstein J. Invest. Dermatology 78, 206 209 (1982). *
P. P. Bradley; D. A. Priebat, R. D. Christensen & G. Rothstein J. Invest. Dermatology 78, 206-209 (1982).
P. Sharon & W. F. Stenson, Gastroenterology 86, 453 460 (1984). *
P. Sharon & W. F. Stenson, Gastroenterology 86, 453-460 (1984).
P. Sharon & W. F. Stenson, Gastroenterology 88, 55 63, 453 460 (1984). *
P. Sharon & W. F. Stenson, Gastroenterology 88, 55-63, 453-460 (1984).

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7589125B2 (en) 2002-07-18 2009-09-15 Palau Pharma, S.A. 2,4-dihydroxybenzoic acid derivatives
US20050267205A1 (en) * 2002-07-18 2005-12-01 J. Uriach Y Compania S.A. 2,4-dihydroxybenzoic acid derivatives
WO2004009528A1 (en) * 2002-07-18 2004-01-29 J. Uriach Y Compañia S.A. 2,4-dihydroxybenzoic acid derivatives
US9610256B2 (en) 2004-02-17 2017-04-04 AmDerma Pharmaceuticals, LLC Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer
US9301931B2 (en) 2004-02-17 2016-04-05 AmDerma Pharmaceuticals, LLC Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and psoriasis
US9018195B2 (en) 2004-02-17 2015-04-28 AmDerma Pharmaceuticals, LLC Use of 2,5-dihydroxybenzene sulfonic acid compounds for treating skin photoaging
US8912171B2 (en) 2004-02-17 2014-12-16 AmDerma Pharmaceuticals, LLC Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and psoriasis
US8497257B2 (en) 2004-02-17 2013-07-30 AmDerma Pharmaceuticals, LLC Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and psoriasis
US8435971B2 (en) 2004-02-17 2013-05-07 AmDerma Pharmaceuticals, LLC Use of 2,5-dihydroxybenzenesulfonic acid in the manufacturing of medicines, applicable to the treatment of angiodependent diseases
US8436045B2 (en) 2004-02-17 2013-05-07 AmDerma Pharmaceuticals, LLC Use of 2,5-dihydroxybenzene derivatives for treating actinic keratosis
US20080249107A1 (en) * 2004-03-18 2008-10-09 Revotar Biopharmaceuticals Ag Non-Glycosylated/Non-Glycosidic/Non-Peptidic Small Molecule Psgl-1 Mimetics for the Treatment of Inflammatory Disorders
US8367677B2 (en) 2004-03-18 2013-02-05 Revotar Biopharmaceuticals Ag Non-glycosylated/non-glycosidic/non-peptidic small molecule PSGL-1 mimetics for the treatment of inflammatory disorders
US8394835B2 (en) 2005-09-20 2013-03-12 Revotar Biopharmaceuticals Ag Aromatic compounds and their use in medical applications
US20110053939A1 (en) * 2005-09-20 2011-03-03 Revotar Biopharmaceuticals Ag Novel aromatic nitro compounds
US7923473B2 (en) 2005-09-20 2011-04-12 Revotar Biopharmaceuticals Ag Aromatic compounds and their use in medical applications
US20110142765A1 (en) * 2005-09-20 2011-06-16 Revotar Biopharmaceuticals Ag Novel phloroglucinol derivatives having selectin ligand activity
US20090105280A1 (en) * 2005-09-20 2009-04-23 Revotar Biopharmaceuticals Ag Novel Aromatic Nitro Compounds
AU2006299181B2 (en) * 2005-09-20 2012-11-29 Revotar Biopharmaceuticals Ag Novel multi-cyclic compounds and their use
US7919532B2 (en) 2005-09-20 2011-04-05 Revotar Biopharmaceuticals Ag Hydroxylated aromatic compounds
US7851501B2 (en) 2005-09-20 2010-12-14 Revotar Biopharmaceuticals Ag Aromatic nitrocatechol compounds and their use for modulating processes mediated by cell adhesion molecules
US20110152291A1 (en) * 2005-09-20 2011-06-23 Revotar Biopharmaceuticals Ag Novel aromatic compounds and their use in medical applications
US20090030015A1 (en) * 2005-09-20 2009-01-29 Revotar Biopharmaceuticals Ag Novel multi-cyclic compounds
US8461207B2 (en) 2005-09-20 2013-06-11 Revotar Biopharmaceuticals Ag Phloroglucinol derivatives having selectin ligand activity
US20080207741A1 (en) * 2005-09-20 2008-08-28 Revotar Biopharmaceuticals Ag Novel Hydroxylated Aromatic Compounds
US20080207639A1 (en) * 2005-09-20 2008-08-28 Revotar Biopharmaceuticals Ag Novel Aromatic Compounds and Their Use in Medical Applications
WO2007039111A3 (en) * 2005-09-20 2007-06-14 Revotar Biopharmaceuticals Ag Novel multi-cyclic compounds and their use
WO2008020026A1 (en) * 2006-08-16 2008-02-21 Action Medicines, S.L. Use of 2,5-dihydroxybenzene derivatives for treating dermatitis
WO2008020042A1 (en) * 2006-08-16 2008-02-21 Action Medicines, S.L. Use of 2, 5-dihydroxybenzene derivatives for the treatment of tissue reactive diseases

Also Published As

Publication number Publication date
EP0601385A1 (en) 1994-06-15
NZ250336A (en) 1995-11-27
CN1092059A (en) 1994-09-14
AU5195693A (en) 1994-06-23
ZA938988B (en) 1994-06-08
JPH06211743A (en) 1994-08-02
CA2110116A1 (en) 1994-06-09

Similar Documents

Publication Publication Date Title
US5374772A (en) Substituted benzoic acids, inhibitors of phospholipases A2
US4015017A (en) Certain biphenyl derivatives used to treat disorders caused by increased capillary permeability
US4650812A (en) 4-oxo-3,4-dihydro-2H-1-benzopyranyloxy alkanoic acid derivatives
US4585788A (en) 6,11-dihydrodibenz[b,e]oxepin-acetic acids and derivatives
US5344843A (en) Cat-1 inhibitors, pharmaceutical compositions and methods of use
JPH0285246A (en) Di-tert-butylhydroxyphenylthio derivative
JPH0481578B2 (en)
JP2554322B2 (en) 2-Substituted-1-naphthols as 5-lipoxygenase inhibitors
US5298652A (en) N-substituted glycines, inhibitors of phospholipase A2
AU765670B2 (en) Synthetic endogenous cannabinoids analogues and uses thereof
FR2472561A1 (en) 4-GUANIDINOMETHYLCYCLOHEXANE CARBOXYLIC ACID DERIVATIVES, PROCESS FOR PREPARING THEM AND THEIR THERAPEUTIC APPLICATION
AU628324B2 (en) Compounds for inhibiting the biosynthesis of lipoxygenase -derived metabolites of arachidonic acid
US4175130A (en) Oxazole- and thiazole-alkanoic acid compounds
HU201509B (en) Process for production of medical compositions containing as active substance derivatives of phenol and process for production of the active substance
WO1993012089A1 (en) New bht ether compounds and their use as hypolipidemic and antiatherosclerotic drugs
GB2190377A (en) Phenyldithiaalkanedioic acids as leukotriene antagonists
EP0206741B1 (en) Leukotriene antagonists
US5464865A (en) 4-aryl- and 4-arylthio-5-hydroxy-2(5H)-furanones as inhibitors of phospholipase A2
EP0002635B1 (en) Process for the preparation of thieno (2,3-c) and (3,2-c) pyridine derivatives, thieno (2,3-c) pyridine derivatives thus obtained, and their therapeutical use
US5191108A (en) Catechol carboxylic acids
JPH08325154A (en) Benzoic acid derivative and phospholipase a2 inhibitor containing the same
EP0002401B1 (en) Derivatives of naphthalene, process for their preparation and their therapeutic application
US4867737A (en) Derivatives of 4-phenyl-4-oxo-2-butenoic acid their preparation process, their use as medicaments and compositions containing them
US4778925A (en) New benzoic acid derivatives, as well as processes for their production and their use as pharmaceuticals
US4906669A (en) Isoprenoid derivatives and anti-ulcer agents containing the same

Legal Events

Date Code Title Description
AS Assignment

Owner name: HOFFMANN-LA ROCHE INC., NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CARSON, MATHEW;HAN, RU-JEN LEE;LEMAHIEU, RONALD ANDREW;AND OTHERS;REEL/FRAME:006792/0826

Effective date: 19931022

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
FP Lapsed due to failure to pay maintenance fee

Effective date: 19981220

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362